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ABSTRACT 
A Hobart mixer was instrumented with a slip ring torque sensor, 
signals were amplified and the output was recorded using a Bascom-Turner 
recorder. The relative dynamic torque on the paddle was measured in 
millivolts as a function of granulating fluid added and time. The data 
generated from a formulation containing lactose, corn starch and 
povidone were reproducibile. The maximum relative standard deviation was 
less than two percent at any time point on the torque curve. 
Formulations containing lactose, dicalcium phosphate and mannitol 
matrices (with four different drugs) showed five distinct phases in the 
torque profile. Phases I, II, and III of the wet granulation process 
were studied for formulations containing five drugs 
(phenylpropanolamine, theophylline, hydrochlorothiazide, phenytoin and 
acetaminophen). Granule properties were evaluated using scanning 
electron microscopy, particle size measurement and determination of bulk 
physical properties, including flow rate as well as compressibility. A 
computer-interfaced instrumented tablet press was used to generate 
compression profiles from which the compressibility of the granules was 
assessed. The instrumented tablet press data substantiated a simple 
theory for the relationship between granulation properties and ease of 
compaction. 
The data suggest optimum flowable and compressible granulations 
can be obtained only from phase III of the process irrespective of the 
drug, drug concentration and matrix. The disintegration and hardness for 
some formulations (theophylline, phenylpropanolamine and 
hydrochlorothiazide) were sensitive to variations in the wet granulation 
process. However, dissolution and friability for these formulations were 
relatively insensitive to changes in the processing variables. 
A (3x2x3) factorial experimental design was used to investigate 
the effect of binder, binder level and granulating fluid on the wet 
granulation process. It was found that all these factors exerted 
statistically significant effects on granulations flow rate, tablet 
ejection force, hardness, disintegration and dissolution at fifteen and 
thirty minutes. A second factorial experimental design (4x5x3) was used 
for the study of the effect of disintegrant, disintegrant concentration 
and percent intragranular disintegrant on the dissolution rate of 
tablets made by wet granulation process. The data indicate that these 
factors exerted statistically significant effects on disintegration and 
dissolution at fifteen and thirty minutes. This instrumentation can be 
used to determine the optimum amount of granulation fluid necessary for 
the wet granulation process. In addition, it can be a valuable tool for 
validation of the wet granulation process. 
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PLAN OF THE THESIS 
This manuscript is divided into seven sections, numbered in Roman 
numerals. The sections are: I. Introduction, II. Experimental, III. 
Results and Discussion, IV. Conclusions and suggestions for further 
work, V. References, VI. Appendices, and VII. Bibliography. The tables 
and figures are numbered in Roman and Arabic numerals respectively. 
In this investigation, torque (mv) on the mixer paddle was 
recorded as a function of time and granulating fluid. In this thesis the 
term "phase of the wet granulation process", is often used. The meaning 
of the term is defined on the page 64. In some instances, the abscissa 
in torque plots was marked from right to left, because of the type of 
chart recorder used. For the purpose of visual clarity, arrows were 
drawn to show the direction of increase in time and Arabic numerals were 
used to denote the phases on the figures rather than Roman numerals that 
were used in the text. 
In some cases, the figures in this manuscript depict plots of 
relationship between two to six different batches. Therefore, for the 
purpose of visual clarity, both solid and dotted lines have been used. 
The dotted lines do not differ in any manner from the solid lines. In 
all cases, no mathematical or empirical relationships are implied; the 
lines are the result of the joining of the data points. All the error 
bars represent standard deviation unless otherwise marked differently in 
the key of the figure. 
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I. INTRODUCTION 
In North America and Western Europe the most widely used dosage 
form in medicine today is the tablet. Tablets may be defined as solid 
pharmaceutical dosage forms containing drug substances with or without 
suitable diluents and prepared either by compression or molding methods 
(1). Tablets remain popular as a dosage form because of the advantages 
afforded to both the manufacturer (e.g., simplicity and economy of 
preparation, stability, and convenience in packaging, shipping, and 
dispensing) and the patient (e.g., accuracy of dosage, compactness, 
portability, blandness of taste, and ease of administration) (2). 
The formulation has undergone rapid change and development over 
the last several decades. Efforts are continually being made to 
understand more clearly the physical characteristics of tablet 
compression and the factors affecting the availability of the drug 
substance from the dosage form after oral administration. With the 
emergence of induced die feeding, precompression, high speed (and most 
recently, ultra high speed) computer controlled presses, the manufacture 
of tablets has become one of the most sophisticated aspects of 
pharmaceutical production. 
The design and formulation of the tablet dosage form as it exists 
today can be thought of as 11 the process whereby the formulator ensures 
that the correct amount of the drug, in the right form, is delivered at 
or over the proper time at the proper rate and in the desired location, 
while having its chemical integrity protected to that point 11 (3). 
Tablet presses continue to improve both as to production speed and 
the uniformity of tablets compressed. Recent advances in tablet 
1 
( 
( 
( 
technology have been reviewed (4 - 7). In order to ensure that adequate 
weight uniformity is maintained, it is important, especially on high 
speed presses, that the materials to be compressed possess acceptable 
flow characteristics. For smooth operation of the tablet press, the feed 
mix must have good compressibility and lubricant properties. Many of the 
active ingredients and excipients do not meet these criteria, and it is 
therefore necessary to prepare a suitable granulation prior to the 
compression processes. Alternatively, a direct compression technique may 
be employed provided that the components meet the above mentioned 
criteria. A third method, dry granulation, is limited to situations 
where neither wet nor direct compression can be used. 
A. Preparation of components for compression 
1. Direct compression 
As its name implies, direct compression consists of compressing 
tablets directly from powdered material without altering the physical 
nature of the material itself. A directly compressible vehicle is an 
inert substance which may be compacted with no difficulty and which can 
be compressed even when quantities of drugs are mixed with it. These 
direct compression materials possess cohesive and flow properties which 
make this compression process possible. 
Since the pharmaceutical industry is constantly making efforts to 
increase the efficiency of tableting operations and to reduce costs by 
utilizing the smallest amount of floor space and labor as possible for a 
given operation, increasing attention is being given to this method of 
tablet preparation, which offers several advantages over wet 
granulation. First and foremost, the process is economical. Also, in 
2 
( 
( 
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tablets made from direct compression the particles do not exist in an 
agglomerate form. Hence upon contact with dissolution medium, a prime 
particle dissociation may be effected. This in turn may result in faster 
dissolution which may indeed be the single most important factor 
controlling product bioavailability (8). Since no moisture is involved 
in the preparation of the blends for direct compression, the tablets 
made from this process tend to be more stable than those produced by wet 
granulation (7). 
However, direct compression has several disadvantages. Many active 
ingredients have poor flow and compression characteristics. Several 
advances have been made in modifying the particle shape and form of 
active ingredients and fillers to render them more suitable for direct 
compression processing. Such success has been achieved with aspirin, 
acetaminophen, and several vitamins. However, these modifications tend 
to increase the price of the raw material, thus negating, to some extent 
at least, the cost advantage of direct compression. 
In most cases, the amount of active ingredient that can be 
incorporated into a matrix (dilution potential) is quite limited 
(usually less than 25 %) (9). On the other hand, adequate distribution 
is sometimes difficult when working with low dosage drugs. Static 
charges develop on the drugs during comminution and mixing which may 
prevent uniform mixing due to lack of or low levels of moisture. This 
segregation problem can also occur as a result of vast differences in 
particle size or density among the components of the blend. The blends 
are most susceptable to unblending particularly in the hopper or feed 
3 
frame of the tablet press. Another limitation of this method is the 
difficulty of achieving deep and uniform color distribution in tablets. 
2. Dry granulation method 
Dry granulation is the process whereby granules of powder blends 
are obtained without the use of heat or solvent. This process has also 
been used for formulations which were found to resist compression when 
prepared by the wet granulation methods (eg. calcium lactate). This 
method is referred to as dry granulation, precompression, or the double 
compression method. The process entails the formation of slugs or 
compacted strips from the active ingredient and one or more 
excipient(s). These slugs are then broken down into a desired particle 
size distribution using a comminuting mill. The lubricant is added to 
the granulation, blended gently, and the material is compressed into 
tablets. 
The type of equipment (slugging by heavy duty tablet press or 
compaction by roller compactor) is selected based on the batch size of 
the material to be processed. In a real sense, slugging I compacting is 
just a rather elaborate method of subjecting a material to increased 
compression time. This process is followed by screening and subsequent 
compression of the particles is roughly equivalent to an extended dwell 
time during the compression cycle. The two or more times that the 
material is subjected to compaction pressures causes a strengthening of 
the bonds which hold the tablet together. It also renders fluid those 
powder mixtures which will not flow well enough to fill the die 
satisfactorily. Excessive pressures which may be required to obtain 
4 
cohesion of certain materials may result in a prolonged dissolution 
rate. 
3. Wet granulation method 
The most general and widely used method of tablet preparation is 
the wet granulation method. In spite of its costly nature requiring 
intensive labor, considerable material handling, and costly equipment, 
the wet granulation process is the only alternative for high dose and 
poorly compressible materials. Although many of the products currently 
being formulated by wet granulation could be made by direct compression, 
existing governmental regulations would define such changes as major 
modifications. These modifications would require changes in ingredients 
or at least, changes in physical form of previously used excipients. 
Hence, the newly formulated product would have to undergo stability, 
bioavailability, and possibly even safety studies, and a new submission 
to regulatory agencies. 
Wet granulation offers several advantages over other methods. This 
method is used to improve: (a) flow, handling and resistance to 
segregration {10), (b) bioavailability (11), (c) homogeneity of low dose 
blends and {d) compression characteristics of tablet matrices. In 
addition, this method can help to overcome electrostatic problems of a 
powder blend (12) or can be used to make in-situ complexes to stabilize 
the dosage form. 
The wet granulation method is not without its limitations. The 
process steps involved in the wet method are (a) weighing, (b) mixing, 
(c) granulation, (d) wet mass screening (some times), (e) drying, (f) 
sizing, (g) lubrication, and {h) compression. The selection of equipment 
5 
( 
for wet granulation is generally made based on the previous experience 
and economic conditions of the manufacturer. The type of equipment 
employed can affect granulation structure (13). Wet granulation is often 
referred to as one of the most difficult unit operations to reproduce 
and scale-up because of the lack of a precise means to measure process 
variables and detect the end point. 
The granulations end point is still usually identified by 
intuitive, subjective judgement. The following subjective end point 
measurments were referred to in well recognized pharmaceutical text 
books: (a) 11 Once the granulation liquid has been added, mixing 
continues until unifonn dispersion is attained and all of the mucilage 
has been activated. This kneading of the mass in large blenders requires 
from 15 minutes to an hour. The length of time depends on the wetting 
properties of the powder mixture and the granulating fluid. A rough way 
of determining the end point is to press a portion of the mass in the 
palm of the hand; if the ball crumbles under moderate pressure, the 
mixture is ready for the next stage of processing 11 (7) and (b) 11 The 
powder mass is wetted with the binding solution until the mass has the 
consistency of damp snow or brown sugar 11 (2). Much of this literature 
gives purely empirical production recipes arrived at by a process of 
trial and error. However, it is by no means certain how many of these 
empirical procedures might turn out to be of more general application 
and based upon sound principles if they were better correlated and more 
widely disseminated. It is important to understand the fundamentals of 
particle size growth in the granulation process before attempting to 
quantify the granulation process. 
6 
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a. Fundamentals of particle size enlargement by wet 
granulation 
Particle size enlargement has been described in the granulation 
process by the following basic growth mechanisms. Growth occurs either 
by the collision and successful adherence of powder particles into 
discrete granules (coalescence) or by growth centered around a nucleus 
onto which particles collide and attach themselves to form a layer 
{layering or onion skinning). Again, this results in discrete granule 
formation (14,15). In both cases, the particles are held together by 
cohesive forces at particle contact points. The overall strength of the 
granules is dependent on the magnitude and nature of the cohesive 
forces, particle size distribution and the number of bonding contact 
points per particle (16,17). 
Forces contributing to the formation of agglomerates from 
particulate solids are one of two kinds {18): natural and applied. The 
natural forces responsible for the formation of agglomerates can result 
from a number of sources: (a) the attraction between powder particles 
due to van der Waals' forces, or electrostatic charges, {b) the 
interlocking effects between particles, depending upon the shape of 
particles, (c) the adhesional and cohesional forces in bridging bonds, 
which are not freely movable, and very importantly, (d) the interfacial 
and capillary forces due to the presence of a liquid phase. 
Rumpf {19) has developed a detailed expression for estimating the 
magnitude of these forces. His calculations indicate that the major 
contribution of the physical forces, in the presence of a liquid which 
completely wets the solid particle surface, is from the capillary forces 
7 
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and dependent on the relative distribution of the liquid and air phases 
in the porous agglomerate (18-24). When the ratio of the liquid to void 
volume of the agglomerate is quite low, the liquid is held in discrete 
lens like rings at the point of contact between particles, and the air 
phase forms a continuous phase. The entrapped liquid is said to be in a 
pendular state. The strength of this pendular bond arises from the 
negative capillary pressure and the surface tension of the liquid rings 
tend to coalesce and form a continuous network, resulting in the air 
phase becoming trapped. The agglomerate is said to be in the funicular 
state. Finally, the agglomerate is said to be in a capillary state when 
the void volume of the agglomerate is completely filled by liquid. 
Mechanical forces are required to bring the individual wetted 
particles, clusters or agglomerate species within the granulator into 
contact with one another so that the natural forces can bring about 
their growth (18). This mechanical action of moving the material is 
imparted by means of rolling, tumbling, agitating, kneading, extruding 
or compressing in suitable equipment. 
In many instances the moisture content which promotes the cohesive 
force between point contacts in the granulate, and also to a degree the 
granulate growth mechanism is only an intermediate step in the 
determination of the physical properties of the final granulation. The 
phase changes from liquid to solid with increasing temperature can 
result in an increase in the final strength of the product. The major 
solid bridges form by crystallization of dissolved material and 
hardening of binders (25-27). 
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b. Moisture content for granulation 
The moisture content of a granulating mass is a very important 
parameter in deciding the successful outcome of the process, and in most 
continuous production processes it is the principal variable used to 
control granulation. 
Newitt and Conway-Jones (23) first noted that the critical 
moisture content required for granulation to occur correlated with 90% 
of the moisture required to saturate the voidage in the powder. This 
void volume is measured by its packed bulk density. The remaining volume 
was assumed to be taken up by entrapped air. Capes and Danckwerts (27) 
found that granule growth occured over a range of moisture contents 
corresponding to 90-110 % of that required to saturate the voidage in 
the packed sand. When they measured the actual voidage of formed 
granules, however, they found that the sand was only closely packed at 
low liquid content. 
Using coarser sand to produce smaller granules, Sherrington (30) 
found that these granules were formed at liquid content much lower than 
that required to saturate the voidage in the sand. A simple geometric 
model was devised for a granule in which the internal pores are 
saturated with liquid but the surface is regarded as 'dry' with the 
liquid withdrawn into interstices between the outermost layer of sand 
grains. 
Many other workers have observed that the rate of granule growth is 
strongly dependent upon the liquid content of the granulating mass 
(23,27-29). This is variously attributed to the increased granule 
plasticity or surface moisture at higher liquid content leading to a 
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greater probability that granules will stick together on collision. 
Kapur and Fuerstenau {28,29) found a more complex growth behaviour for 
pulverised limestone and defined three growth regions- the nuclei growth 
region, a transition region and a ball growth region. For the nuclei 
growth region, they suggested a relationship of the form 
K = K1 exp {K2 W) 
between their growth rate constant K and the granulator water content W, 
where K1 and K2 are constants for a given powder of given surface area. 
Growth rate in the ball growth is slower and less sensitive to moisture 
content and its dependence on water {30) content has the opposite 
curvature to that of an exponential function (31). 
When one or more of the components of the material being 
granulated is soluble in the granulation fluid it is the total volume 
fraction of liquid or solution phase rather than the moisture content 
per se which controls the granulation behaviour (32-34). 
In the absence of any accepted predictive method, Capes et al. 
(35) have attempted to fit all of the available data on granulation 
moisture to a simple formula. The fit is very approximate and two 
constants are needed, for particles less than and greater than 30 ,µm: 
For fine particles ( <30 il m) 
W = 1/ l+ 1.85 {Ps/P1) 
For coarse particles ( 1' 30 i]!:m) 
W = 1 I l+ 2. 17 (Ps/P1) 
( 1) 
(2) 
W = weight fraction of binding liquid for agglomeration 
Ps= true density of particles 
P1= density of binding liquid 
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Leuenberger et al. (36-39) modified the Capes equation by adding a 
constant to take into account packing of the particles and provide a 
factor for equilibrium moisture uptake of the material. 
(3) 
In the equation (3), the authors took into account that cohesive 
forces arise even before the entire pore space is filled. 
Y = 0.213 (mean value for cubic and rhombohedral particle packing) 
£ = porosity {obtained by tamped density measurements) 
0H= equilibrium moisture uptake of the solid materials when exposed 
to 100% relative humidity 
These authors showed good correlation between the theoretical 
predictions and experimental data generated by the power consumption 
measurements. 
c. Quantification of the wet granulation process 
In the pharmaceutical industry, the wet granulation process is 
mainly performed as a manual, batch process. The result of the process 
depends on the skill of the operator, who estimates the process largely 
by visual inspection. To be able to quantify the process, it is 
necessary to possess objective measuring values of parameters which 
reflect real changes in the wet granulation process. 
Recognizing this problem several researchers have attempted to 
quantifiably characterize the wet granulation process. For example, 
Toyoshima et al. {40) have used a strain gauge on a beam connected to 
the wall of a rotary wet granulator for measuring the pressure on the 
wall. 
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The power consumption of the mixer motor has been investigated by 
Hunter and Ganderton (41) for three different mixers (planetary, Z-blade 
and Lodige mixers). The method is rather imprecise since the actual 
fraction of the energy supplied as useful work to the mixer shaft is 
unknown. These authors did not attempt to correlate the power 
consumption to any independent or dependent variables. 
Lindberg et al. (42) instrumented a change can mixer, (Artofex 
PH-15) with strain gauges in half bridge. Strain gauges were glued 
vertically on to the left mixer arm and protected from moisture by a 
curing silicone rubber coating. These authors concluded, that neither 
strain gauges nor Hall effect multiplier (power measurement equipment) 
in combination with an oscilloscope or a chart recorder are suitable 
instruments during routine granulation. In addition, they stated, 
bending moment and power consumption are suitable parameters in studying 
the granulation process. 
Travers et al. (43) constructed a 'torque arm' mixer of about two 
kilogram capacity, where the mixer arm was driven by a motor mounted on 
a platfonn to move in a horizontal plane on a ball-bearing race. A pin, 
fixed on the circumference of that platfonn, bears on the arm of a 
correx tension gauge and resists the torque developed as the mixer arm 
rotates in the mass. The angular displacement of the platform, which for 
small displacement is proportional to the developed torque, operates a 
displacement transducer. This eqipment has serious engineering 
constraints which preclude scale-up. 
Lindberg et al. (44) attached a horizontal bar with full strain 
gauge bridge to a planetary mixer (Tripas planet PL-25) paddle. The 
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signals were processed using telemetric equipment and were registered on 
an oscilloscope or a chart recorder. These authors concluded that the 
telemetric equipment was useful for the instrumentation of a mixer, but 
it was not suitable for routine measurements in its present 
construction. 
Leuenberger et al. (36-39) fitted a planetary mixer with 
instruments that allowed measurement of power consumption during the 
addition of granulating liquid. These authors did not publish the 
details of the instrumentation, because of their affiliation with 
private industry. Power consumption (watts) of the mixing motor as a 
function of continuous addition of granulating liquid was studied. In 
addition, these authors developed an equation (by modifying Capes et al. 
(35) equation) to predict the granulating fluid necessary for optimum 
granulation process. These authors showed that the calculated amount of 
granulation fluid necessary for optimum granulation within the phase III 
of the granulation process. In addition, these authors concluded that 
the absolute power requirement may differ with different mixers 
(planetary, z-mixer) using the identical granulating material but mixing 
phases one, two and three, and which are relevent to identify the end 
point, are clearly recognizable in both cases. 
Lindberg et al. (45) equipped a small planetary mixer (Kenwood 
Major 707 A) with a reconstructed dog clutch. The load on the beater was 
transmitted to a coil spring. The stretch of the spring was recorded by 
an optic-electronic device. Although the instrumentation was very simple 
and cheap, it had the drawbacks of hysteresis and friction of the spring 
(46). The above authors reconstructed the same mixer and equipped with a 
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torque transducer consisting of a steel beam, with strain gauges in a 
full bridge circuit {46). The instrumentation required considerable 
reconstruction of certain parts of the machine. 
Spring {47) modified a planetary mixer, so that the conductivity 
of the damp mass could be studied during the process of wet massing. 
The traditional methods of timing and operator assessment are of 
limited use as primary strategies in high speed mixer-granulation 
(closed system) due to the inherent difficulties in standardising the 
end point condition. However, there is no doubt that they still provide 
an important additional check on the granulation end points determined 
by other control methods. 
On the basis of observation of the current required during 
granulation experiments with a Lodige high-speed mixer, it was decided 
that the granulation cycle was apparently capable of being instrumented 
{48). Diosna P600, equipped with ammeters, indicated both the 
consumption of the impeller and that of the chopper {49). Systems based 
on current and power devices, or measurement of torque and mass 
temperature, were considered inconvenient. Therefore, a system 
(Boots-probe) was constructed which made it possible to detect changes 
in momentum of granules moving in a constant velocity region of the 
mixer bowl {50-52). Power measurements were also adapted with intensive 
mixers (39). Measurements of the power input to the impeller and the 
chopper motor of Diosna P25 was used in controlling the granulation 
process {53). Another technique which has been investigated includes the 
sound generated at the mixer shaft {54). 
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In recent years, pharmaceutical companies have grown in size and 
complexity, the relative role of their individual scientists has 
decreased proportionately through a phenomenon known as 
compartmentalization. It is rare, except possibly at higher managerial 
levels, to have total technical responsibility for an entirely new drug 
process from the developmental phase through final manufacturing and 
quality control operations. Even when technical managers have such 
sweeping authority, they are usually not well versed in the details and 
complexity of the product manufacturing processes they operate. 
At the scientific end of the organization, formulating scientists 
may be responsible for preparing only the first preclinical and clinical 
supplies of the drug, while others are only responsible for pilot work. 
Engineers may be assigned responsibility for equipment and facilities 
while others work on process - optimization assignments. There may be 
one person with a total view of the "big picture". 
The traditional approach to this particular managerial dilemma is 
to form a special projects team with crossing or overlapping lines of 
authority to each important new product. This approach sometimes proves 
successful but often does not. Currently the official approach to solve 
this problem is to validate pharmaceutical production processes. 
FDA in its recently proposed guidelines has offered the following 
definition for process validation: 
"Process validation is a documented program which provides a high 
degree of assurance that a specific process will consistently produce a 
product meeting its predetermined specification and quality attributes". 
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Process validation studies of new drug products often are carried 
out during the phase III of process development and product batch 
scale-up, and often with the participation of representatives from 
product development, engineering, manufacturing and quality control 
units. Such a natural interplay of technical as well as organizational 
talents forms a more desirable alternative to artificially created 
special project teams. 
Arumbolo (55) advocated the following priority list for product 
validation: 
Large volume parenterals 
Small volume parenterals 
Opthalmic and biologicals 
Sterile solids 
Low dose I high potency oral solids 
Other tablets and capsules 
Oral liquids and topicals 
Products that can cause the most problems, if they are not 
manufactured by a completely controlled process, are given at the top of 
the list, however, it should be stressed that validation and quality of 
all of the products are important. 
Although validation of existing tablet dosage form is not on top 
of the priority list, validation work for the new tablet dosage form as 
early as the preformulation stage is a logical step. Eventually the FDA 
will require all pharmaceutical processes to be fully validated. 
All pharmaceutical scientists, whether in Development, Quality 
Assurance, Production, or Regulatory Affairs, are familiar with the 
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concept that quality is not tested into a product but rather built into 
a product. This is an important concept, since it serves to support the 
underlying definition of validation, which is a systematic approach 
aimed at identifying, measuring, evaluating, documenting and 
reevaluating a series of critical steps in the manufacturing process 
that require control to a reproducible final product. 
There are several important reasons for validating a product and I 
or process. First, manufacturers are required by law to comform to 
Current Good Manufacturing Practice (CGMP) regulations (56). Second, 
good business practice dictates that a manufacturer avoid the 
possibility of rejected or recalled batches. Third, validation helps to 
ensure product uniformity, reproducibility, and quality (57-59). 
Most discussions (60-62) of product and process validation that 
have been recently published concentrate on validation associated with 
the full-scale manufacture of pharmaceutical processes and how equipment 
processing variables affect the overall quality of the finished product. 
Although this is certainly an important aspect of product validation, 
validation of numerous earlier aspects of development are critical to 
the subsequent phases of the process. 
Without proper characterization, specification and control of 
these earlier developmental steps, the foundation will be weak and will 
not support the evolving product when it is challenged during the formal 
validation of pilot and production batches. 
The validation process of a solid dosage form begins with a 
validation of the raw materials: both active ingredient and excipients 
(63). Variation in raw materials constitutes one of the major causes of 
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the product variation from specification. Characteristics such as drug 
morphology, particle size, surface area, color, and other physical, 
chemical or biological properties are important in assessing drug 
availability and reproducibility of subsequent manufacturing processes 
(64). Particle size is directly interrelated to several key processing 
variables. Several of the most significant are flow, blend uniformity, 
granulation solution uptake, compressibility and lubricant efficiency 
(65). A comprehensive program for establishing validation and control 
procedures for raw materials is critical if one hopes to achieve 
product criteria batch after batch. Guidelines for process validation of 
solid dosage forms have been discussed by Rudolf (66). 
C. Objectives of the present study 
The wet granulation process has been used in the pharmaceutical 
industry for many years and yet the detection of the desired wet 
granulation end point is still usually made by intuitive, subjective 
judgement. From a state of absolute empiricism, some progress has been 
made in our understanding of the fundamentals of the subject to permit 
some qualitative rationalization of the results obtained. For the 
pharmaceutical scientist faced with developing a process for a new 
granulated product, however, these developments do no more than point 
the way, and a high degree of intuition and the willingness to undertake 
what may well turn out to be a long frustrating program of trial and 
error may still be needed. Progress in optimization and validation is 
seriously inhibited due to a lack of an objective, quantifiable, 
reproducible measuring technique. 
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The objectives of this study were: 
1. To instrument a laboratory size planetary mixer using 
commercially available electronic equipment in order to measure relative 
torque on the mixing paddle. It was hoped that the instrumentation could 
be used to quantify the end point of the wet granulation process. In 
addition, it was planned to investigate the reproducibility of the data 
generated by the instrumented mixer. 
2. To examine the granulation process of different drugs and to 
evaluate the physical properties of granules and tablets made by the wet 
granulation process. 
3. To determine the effect of some formulation and processing 
variables on the properties of granules and tablets produced by wet 
granulation and also, to investigate the properties of tablets so 
produced in order to distinguish which properties are more sensitive to 
granulation process variables and which are 11 robust 11 • 
It ~as hoped that this study has value of both theoretical and 
practical importance to the pharmaceutical industry. The instrumentation 
of a Hobart mixer was planned in January 1982 and the parts were 
ordered. Due to the manufacturing delay of a torque sensor, the 
instrumentation was completed in August 1982. Since 1982, some progress 
has been reported by other authors in the field of granulation studies. 
The results of those authors (post 1982) will be discussed in the 
results and discussion section in comparison with the data obtained in 
the present study. 
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II. EXPERIMENTAL 
A. Materials 
1. Formulation components 
Theophylline anhydrous (Lot# R39717-2716) 1 
Phenylpropanolamine hydrochloride (lOOF-0393) 1 
Acetaminophen (53F-0305) 1 
5,5,- Diphenyl Hydantoin (phenytoin) (124F-0177)1 
Hydrochlorothiazide (NX018) 2 
Povidone C-30 (R45642-0444) 3 
Crospovidone (1433-3) 3 
Methyl cellulose 15LV (Methocel) (R30123-0375) 4 
Hydroxypropyl cellulose (Klucel) (R17682-0214) 5 
Corn starch (R52408-1131) 6 
Starch 1500 (pregelatinized starch) (404028) 7 
1sigma Chemical Company, St. Louis, MO 
2E.R. Squibb & Sons Inc., Princeton, NJ 
3G.A.F. Corporation, New York, NY 
4oow Chemical Company, Saddle Brook, NJ 
5Hercules Inc., Wilmington, DL 
6Ruger Chemical Co., Irvington, NJ 
7colorcon Corporation, Philadelphia, PA 
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Explotab (sodium starch glycolate) (2166) 8 
Emcompress (dicalcium phosphate dihydrate unmilled)(9187) 8 
Ac-Di-Sol (croscarmellose sodium) (T309) 9 
Avicel PHlOl (microcrystalline cellulose) (14361) 9 
Lactose hydrous (lactose) (R52903-1212) 10 
Lactose anhydrous (4NL13)lO 
Dicalcium phosphate anhydrous (R41864-0711) 11 
Mannitol (R30222-1222) 12 
Magnesium stearate (R49610-0370) 13 
3A Denatured alcohol (3A ethanol) (R45246-1419) 14 
Isopropyl alcohol (isopropanol) (R55534-1416) 15 
Hydrochloric acid (026490) 16 
Monobasic Potassium phosphate (722964) 17 
Sodium hydroxide (720859) 17 
8Edward Mendell Co., Caramel, NY 
9 FMC Corporation, Philadelphia, PA 
10sheffield Company, Memphis, TN 
11Monsanto Pharmaceuticals, St. Louis, MO 
12Pfizer Inc., New York, NY 
13Mallinckrodt Inc, St. Louis, MO 
14u.s.I. Chemical Company, Newark, NJ 
15J.T. Baker Chemical Co., Phillipsburg, NJ 
16E.I. Dupont De Nemours & Co. (Inc), Wilmington, DE 
17Fisher Scientific Company, Fair Lawn, NJ 
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2. Equipment 
Hobart mixer (model# Cl00) 18 
Slip ring torque sensor (model# 1102-200) 19 
Rubber block couplings 19 
Explosion proof motor (1/4 HP) 20 
Strain gauge conditioner indicator21 
Bascom-Turner recorder22 
Aluminum plates23 
Burette24 
Mettler balances (models# PC4400,PR1200) 25 
Mettler digital/analog converter (model# GC47) 25 
Stokes hot air oven26 
Stokes model F tablet press hopper26 
Stokes model 82 rotary tablet press26 
Stokes oscillating granulator26 
18Hobart Manufacturing Co., Troy, OH 
19Lebow Products, Eaton Corporation, Troy, MI 
20General Electric, Fort Wayne, IN 
21Analog Devices, Norwood, MA 
22sascom-Turner Instruments, Newton, MA 
23Pfizer Inc., New York, NY 
24Thomas Scientific, Philadelphia, PA 
25Mettler Instrument Corporation, Princeton, NJ 
26stokes - Penwalt Co., East Stroudsberg, PA 
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Twin - Shell blender27 
Turbula rapid blender28 
Manesty Beta press 29 
Manesty model F3 tablet machine hopper 
Fitzpatrick comminuting machine (model M) 30 
Heberlein hardness tester31 
Erweka hardness tester, type TBT (NR 19306) 32 
Friabilator (Roche) 33 
Thickness gauge34 
USP disintegration apparatus 34 
USP dissolution apparatus34 
Tap density tester34 
Apple computer (model Ile) 35 
Printer36 
27Paterson - Kelly Co., East Stroudsberg, PA 
28wiley A. Bachoven Co., Troy, OH 
29Thomas Engineering Inc., Hoffman Estates, IL 
30w.J. Fitzpatrick Co., Chicago, IL 
31cherry - Burrel Corporation, Cedar Rapids, IA 
32 Erweka Apparatabau, W. Germany 
33Mitertoya, Japan 
34vanderkamp, Vankel Industries, Chatham, CA 
35Apple computer company, Cuperton, CA 
36 Integaral Data Systems, Milford, NH 
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Perkin - Elmer Hitachi 200 spectrophotometer37 
C M . . h k 38 enco - e1nger sieve s a er 
Ohaus moisture balance39 
37Hitachi, LTD., Tokyo, Japan 
38central Scientific Company, Chicago, IL 
39ohaus scale corporation, Florham Park, NJ 
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B. Methods 
1. Instrumentation of Hobart mixer 
A Hobart mixer consists of (a) bowl support, bowl and lift unit, 
(b) base and pedestal unit and (c) transmission case unit. The back 
cover from the base and pedestal unit was opened. The transmission unit 
was taken off from the pedestal unit and its cover was removed and 
wiring disconnected. The motor was pulled from the transmission case 
unit and the windings removed from the shaft. A 0.375 X 22.0 X 6.5 in. 
aluminum support plate was installed on the pedestal unit. The 
transmission case unit cover was bored to make it possible to connect 
its driving shaft to the driving shaft of the slip ring transducer and 
the transmission case unit was then installed on top of the aluminum 
plate. The slip ring transducer was aligned accurately between the 
transmission unit and the 1/4 HP explosion proof motor using aluminum 
support blocks. The driving shafts were connected with rubber block 
couplings, which could accomodate an angular misalignment of 1°, 
parallel misalignment of 1/16 to 1/4 inch and axial play of 1/16 to 1/2 
inch. The entire unit was installed on second aluminum plate (0.375 X 
28.75 X 6.5 inches) and the end of the top aluminum plate was supported 
with one inch diameter aluminum post for stability. The back plate of 
the bowl support was shortened by about 0.375 inch to accomodate the 
aluminum plate which supports the slip ring unit and motor. The position 
of the bowl support was adjusted by turning the bowl lift stud. The 
transducer unit was connected to the amplifier (strain gauge conditioner 
indicator), while the amplifier in turn, was connected to the 
Bascom-Turner (Model# 4120) recorder. 
25 
Torque sensors consist of specially designed structures which 
perfonn in a predictable and repeatable manner when a force is applied. 
This force is translated into a signal voltage by the resistance change 
of strain gauges which are applied to the torque sensor structure. The 
change in resistance indicates the degree of deformation, and in turn, 
the load on the structure. The strain gauges are connected in a four arm 
(Wheatstone bridge) configuration, which acts as an adding and 
subtracting electrical net work and allows compensation for temperature 
effects as well as cancellation of signals caused by extraneous loading. 
The strain gauge bridge is connected to four silver slip rings mounted 
on the rotating shaft. Silver graphite brushes rub on these slip rings 
and provide on electrical path for the incoming bridge excitation and 
the outgoing signal. 
A voltage of 5 V (D.C) was used to excite the strain gauge bridge. 
A force applied to the structure unbalances the Wheatstone bridge, 
causing an output voltage to appear. The gain was set at 179.6 such that 
1 volt output equalled 100 in.oz. of applied load (Figure 1). 
2. Wet granulation using instrumented Hobart mixer 
A previously mixed powder blend (0.5 or 1.0 kg ) was placed in a 2.8 
liter bowl and was blended for five minutes at slow speed (145 RPM) 
using the instrumented Hobart mixer. Granulating fluid was added at a 
constant rate, using a burette, while mixing at low speed. Output in 
millivolts as a function of time was recorded using a strip chart 
recorder. The strip chart recorder was set on 0.5 volt and ten cm/minute 
settings. Different phases of the torque profile were identified. The 
experiments for phase I, II and III were repeated in order to quantify 
26 
( 
a: 
w 
x 
-~ 
I-
a: 
c:t 
r- cc 
w 0 a:: ~ ::::> 
<..!J c ........ 
w ( LL... 
I-
z 
w 
~ 
:> 
a: 
I-
UJ 
z 
( 
\ 
... 
c 
0 
== c.
:: 
'$. 
.K 
u 
c = 
- c ID -
... 'a 
Cl> = 
.c c i c.> 
c:: 
... 
c 
Cll 
=c C CD c: Cl) 
Q. CD 
- = 
- er Cl) ... 
c 
~ 
... 
CD 
E 
= ~ 
E 
c 
:;: 
c 
ID 
27 
... 
5 
. 'a 
E 
< 
@ 
@ 
( 
( 
reproducibility. Wet mass from phases IV and V were beyond the normal 
granulating process and were discontinued in this study. Wet 
granulations were dried at 50°c to less than one percent moisture level. 
Dried granulations were sized and studied for physical characteristics, 
such as particle size distribution, flow properties, bulk properties and 
tabletability using an instrumented tablet press. 
3. Granulation characterization 
a. Particle size analysis 
A nest of sieves, sizes (U.S. standard) 20,40,60,80,100,140,200 
and 325, was used to measure the partic~e size distribution. A 100 gram 
sample was placed on the top screen and the sieve stack was shaken for 
20 minutes on a Cenco Meizer sieve shaker. The shaker was set on # 6 
setting. The cumulative weight percentage of powder at each sieve level 
was calculated. 
b. Bulk density 
The bulk density determination procedure developed by Butler and 
Ramsey (67) was adapted, with a modification that a graduated measuring 
cylinder was tapped 2000 times instead of a few times by a tap density 
tester. A sample of 50 cm3 of powder was carefully introduced using a 
glass funnel into a tared 100 cm 3 graduated cylinder, weighed and tapped 
using the above tap density tester. If V is the tapped volume in cm3 of 
W grams of material in the cylinder, then the tapped bulk density in 
g/cm3 is given by: 
Pb = W I V 
and loose bulk density P1 
P1 = w I 50 
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compressibility of material was calculated by: 
% C =(Pb - P1) I Pb X 100 
In theory, as compressibility of the powder increases, the 
flowability decreases (68). 
c. Flow measurements 
Granule flow was measured using a recording powder flowmeter. The 
flowmeter consists of a digital balance, digital/analog converter, 
Bascom-Turner recorder, and a stainless steel tablet machine hopper. The 
hopper was fixed so that the orifice of the hopper was 12 ems. above the 
balance (Figure 2). Sample size was varied depending on the batch size. 
Flow index (Linearity) was determined using the procedure developed by 
Jordan and Rhodes (69). The recorder was calibrated such that the sample 
weight, when placed on the balance (tared with holding pan) would cause 
the recording pen to deflect the entire scale. A sample of the material 
to be evaluated was placed in the hopper. When the orifice of the hopper 
was opened, the powder fell on the pan, causing the pen to respond in a 
manner characteristic of the powder system. The recorder was set on a 
trigger before the opening of the hopper orifice. The falling weight of 
the powder was recorded as a function of time. The pen tracings (flow 
gram) were then analyzed for linearity and mass flow (grams / second). 
The linearity term was calculated from the formula: 
Linearity= (r2 - 0.8) X 100 
where r2 is the coefficient of determination. Three replicate flow grams 
were determined for each granulation system. The values for mass flow 
and linearity were averaged. 
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d. Electron microscopy 
The granulations were placed on an adhesive coated steel stub and 
were then coated with a gold palladium mixture {50/50). The coated stubs 
were then placed in a scanning electron microscope and photographed with 
a Polaroid camera which captures the image of the sample as the electron 
beam illuminates it. The various micrographs used in this study were 
taken with the assistance of Mr. Kevin Ramey of the Howmedica division 
of Pfizer Inc., located at the Groton, Connecticut facility. 
e. Moisture determination 
The moisture content of each granulation after drying was 
determined using an Ohaus moisture balance operating at a temperature of 
ao0c for lactose based granulations and 1050C for dicalcium phosphate 
based granulations, for 30 minutes. 
f. Compression 
Part of the study was done using an instrumented Manesty Beta 
press, located at Pfizer Central Research, Groton. The tablet press was 
instrumented with strain gauges. Compression force was measured by the 
strain gauges which were bonded to the tie rod and the ejection force by 
the strain gauges glued to a cantilever beam. One end of the cantilever 
beam was pressed against the ejection cam and the other end was attached 
to the body of the press. Strain gauges were calibrated with weights. 
These bridges were energized by 24 volts (D.C) and the gain was set, so 
that one volt of output equals to 10,000 pounds for compression and 
1,000 pounds for ejection respectively. The output was acquired and 
recorded using a two channel Bascom-Turner recorder which converts 
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analog signals to digital signals and stores the data on a floppy disc. 
The output was also monitored by using an oscilloscope. 
A major part of compression work was done by an instrumented 
Stokes B2 rotary tablet press located in the Department of Pharmaceutics 
of the University of Rhode Island. This tablet press was instrumented 
with four piezo-electric transducers and interfaced with an Apple Ile 
computer. One transducer was installed by horizontally sectioning the 
eye bolt to measure compression force and the remaining three 
transducers were installed underneath the ejection cam in a series to 
* measure ejection force. The software for the Apple Ile computer enabled 
the calculation of peak height (compression and ejection curves) by 
picking signals off the press at the rate of 100 data points per 
millisecond. A mean peak height from data on ten tablets was calculated. 
In addition, it also calculates mean area under the compression, 
ejection curves, mean area to height ratio for compression and standard 
deviation for all the above parameters. 
4. Tablet characterization 
a. Weight 
The weight of each individual tablet was determined after 
dedusting, and placing it on an electronic balance. This procedure was 
repeated for ten tablets in most cases, and sometimes for twenty tablets 
if the variation was significantly large (over 2%). The data from the 
tablets were analyzed for sample mean and standard deviation. 
* The author gratefully acknowledges the use of software developed by Mr. 
John R. Hoblitzell. 
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b. Thickness 
The thickness of ten tablets was determined by first dedusting, 
and then placing it in the jaws of micrometer. The measurements were 
recorded and analyzed for mean value and standard deviation. 
C. Hardness 
The hardness of ten tablets was determined for each system by 
placing each individual tablet in a hardness tester (Heberlein or 
Erweka) which recorded the breaking strength of the tablet in kilograms. 
This procedure was repeated and the data were analyzed for sample mean 
and standard deviation. 
d. Friability 
This test is a measure of the abrasion resistance and was 
determined by first weighing twenty tablets after dedusting, then 
placing them in a tumbling chamber for four minutes at twenty five RPM. 
The tablets were dedusted and weighed after tumbling, and the percent 
friability was determined as follows: 
% Friability = ((Intial weight - final weight) /Intial weight)xlOO 
e. Appearance of finished products 
Tablets were examined using a lOX magnifying glass for chipping, 
cracking, picking or mottling of the surface as an in-process check. 
f. Ease of manufacturing 
The noise and vibration from the tablet press was carefully 
monitored subjectively to identify any problems in manufacturing 
tablets. 
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g. Disintegration 
Tablet disintegration was tested by using the USP apparatus, as 
described in the U.S.Pharmacopoeia and the National Formulary (1) 
without discs. The time needed for all the palpable fragments to pass 
through the screen at the bottom of the cage was detected visually, and 
was recorded. Six tablets were used in each test and mean and standard 
deviation were calculated. 
h. Dissolution 
When a drug was to be measured for rate and extent of dissolution, 
a sample of the lot of drug to be used was placed in various 
concentrations in a spectrophotometer to measure the l max for that 
particular drug. Once this value was determined, the spectrophotometer 
was set at that wavelength, and each sample was analyzed for absorbance. 
The result was recorded on a Beer's plot and correlation between 
absorbance and concentration was recorded. The monograph, as it appeared 
in the USP (1) was used as a reference for determining the dissolution 
medium for the test. A sample of six tablets was used for each system. 
The samples at specified time intervals were withdrawn and diluted with 
dissolution medium to read the absorbance between 0.1 to 0.7. The data 
were analyzed using a computer program (appendix I). 
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5. List of fonnulations used in this study 
TABLE I 
Ingredients 
Lactose 
Corn starch 
Povidone C-30 
Fonnulation 1 
% weight per batch 
85.0 
10.0 
5.0 
100.0 
Three batches each of one kilogram weight, were prepared. All the 
excipients in a batch were blended together in a ''V" shell blender for 
ten minutes. The powder mix was passed through a 40 mesh screen and 
reblended fifteen minutes. The powder blend was placed in a 2.8 liter 
Hobart bowl and dry mixed for five minutes. The powder mix was wet 
granulated using the slow speed of the instrumented Hobart mixer by 
adding water (200 g) at a constant rate (34.3 ml/minute) while recording 
the torque (mv). This procedure was repeated two more times. The output 
voltage for all three experiments was recorded one on top of the other 
by changing the base line and using the same starting point on the 
chart. The torque values were digitalized for every twenty second 
interval. Mean and relative standard deviation were calculated to 
determine the reproducibility of the output. 
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TABLE II 
Phenylpropanolamine, Theophylline, and Hydrochlorothiazide Tablet 
Formulations. 
Formulation 
2 3 4 
Ingredients % weight per tablet 
Phenylpropanolamine hydrochloride 10.0 
Theophylline anhydrous 10.0 
Hydrochlorothiazide 10.0 
Lactose 83.5 83.5 83.5 
Povidone C-30 5.0 5.0 5.0 
Ac-Di-Sol 1.0 1.0 1.0 
Magnesium stearate 0.5 0.5 0.5 
Drug, lactose and povidone were blended together in a "V" shell 
blender for ten minutes. The powder blend was passed through a 40 mesh 
screen and reblended for fifteen minutes. The powder mix (985.0 g) was 
dry mixed and wet granulated in a 2.8 liter bowl fitted to an 
instrumented mixer. The mixer was operated at a slow speed and the 
granulation fluid, 3A denatured alcohol (295.5 g) was added at a 
constant rate (31.5 ml/minute) while recording the output. Different 
phases of the torque profile were identified for each formulation. 
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Triplicate batches for phases I, II, and III were repeated for each 
formulation. "The experiments repeated for phases I, II, and III refer 
to the terminal point on the curve for phase I, II, and III on the 
torque profile". The wet granulations were dried (four hours) at 5o0c in 
a forced hot air oven for a moisture content less than 1%. A sample of 
the dried granulations was screened through #10 mesh screen and 
photographed by scanning electron microscopy. The remaining granulations 
were sized through #18 mesh fitted to an oscillating granulator. These 
granulations were tested for particle size distribution, bulk 
properties, and flow properties. 
Ac-Di-Sol was added to the granulation and blended fifteen 
minutes. The lubricant (magnesium stearate) was added and blended for 
five minutes. The tablet blend was compressed on an instrumented rotary 
tablet machine fitted with four sets of 1/4 inch standard round concave 
tooling. The tablet weight was maintained at 135 mg. and the 
compressional force was set at 10 KN. These tablets were tested for 
weight variation, thickness, hardness, friability, physical appearance, 
disintegration and dissolution. 
Phenylpropanolamine and theophylline formulations were also 
studied for extended wet mixing after discontinuing the addition of 
granulating fluid. Wet mixing was continued until ten and twenty minutes 
for each phase of the formulation. The wet granulations were dried, 
sized, and studied for all the parameters listed above. 
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TABLE II I 
Phenytoin tablet formulations 
Formulation 
5 6 
Ingredients % weight per tablet 
Phenytoin 20.0 18.18 
Lactose 73.5 66.82 
Povidone C-30 5.0 4.55 
Ac-Di-Sol 1.0 0.90 
Starch 1500 9.10 
Magnesium stearate 0.5 0.45 
------ -------
100.0 100.00 
Phenytoin, lactose and povidone were blended together, passed 
through a 40 mesh screen, and reblended. The mixture was wet granulated 
with 3A denatured alcohol, using the same procedure as in previous 
formulations. All five phases were identified and the experiments were 
repeated for phases I, II, and III. The wet granulations were dried at 
5o0c for four hours in a forced hot air oven. Dry granulations were 
sized through #2A (0.093 inches opening) plate fitted to a Fitazpatrick 
model M comminutor, Knives forward and slow speed. Granulations were 
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evaluated for physical properties and then Ac-Di-Sol was added and 
blended fifteen minutes. Each batch was subdivided into two portions. 
For one of the two portions 9.1 percent Starch 1500 by weight to the 
total formulation was added and blended fifteen minutes. Magnesium 
stearate was added to both blends and blended for five minutes. Tablets 
were compressed using an instrumented Stokes 82 tablet press fitted with 
four sets of 3/8 inch standard round concave tooling. Tablet weight was 
set at 250 and 275 mg for formulations 5 and 6 respectively. 
These tablets were tested for all physical parameters. In 
addition, these tablets were also tested for dissolution, compared 
against commercially available Parke Davis 50 mg active tablets and also 
* tablets made with drug - S-cyclodextrin complex • 
* Tablets containing 50 mg drug were supplied by Mr. R.P. Hegde 
{70). The author gratefully acknowledges help from Mr . Hegde. 
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TABLE IV 
Acetaminophen granule formulations 
Formulation 7 
Phase I II II I 
Ingredients % weight per batch 
Actaminophen 94.50 94.22 93.72 
Povidone C-30 (dry) 4. 72 4. 71 4.68 
Povidone in 10% a le oho 1 i c solution 0.78 1.07 1.60 
-------- ------- --------
100.00 100.00 100.00 
Acetaminophen was blended with povidone, the blend was passed 
through a 40 mesh screen, and reblended for ten minutes using the 
Turbula blender. This powder mix (500 g) was mixed another five minutes 
in a Hobart bowl and wet granulated with 10% solution of povidone in 
alcohol, by adding the solution at a constant rate. Five phases of the 
wet granulation process were identified and the experiments were 
repeated for phase I, II, and III. These wet granulations were dried at 
5o0c for four hours in a forced hot air oven for moisture content less 
than 1%. Dried granulations were sized through # 2A plate fitted to a 
Fitzpatrick model M comminuting machine. These granulations were tested 
for all granule physical properties and then used in tablet formulation. 
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Ingredients 
TABLE V 
Acetaminophen tablet formulations 
Formulation 8 
Phase I II 
% weight per tablet 
Acetaminophen granulation 74.09 74.31 
Avicel PH 101 24.41 24.19 
Ac-Di-Sol 1.00 1.00 
Magnesium stearate 0.50 0.50 
-------- --------
100.00 100.00 
I II 
74.70 
23.80 
1.00 
0.50 
---------
100. 00 
Three tablet blends were made using granulations from phase I, II, and 
III of formulation 8, utilizing the following procedure. Acetaminophen 
granulation, Avicel PH 101, and Ac-Di-Sol were blended together for ten 
minutes, using the Turbula blender. Magnesium stearate was added to the 
above powder blend and blended five minutes. Tablets were compressed 
using an instrumented Stokes 82 tablet press. Tablet weight was set at 
464.3 mg (i.e 325 mg of drug). The compression force was set at 16.0 KN; 
(This value was selected after examination of the compression profile). 
Tablets were tested for all the properties listed in the tablet 
characterization section. 
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TABLE VI 
Theophylline tablet formulations 
Formulation 
9 10 11 
Ingredients % weight per tablet 
Theophylline anhydrous 10.0 40.0 75.5 
Lactose 83.5 53.5 18.5 
Povidone C-30 5.0 5.0 5.0 
Ac-Di - Sol 1.0 1.0 1.0 
Magnesium stearate 0.5 0.5 0.5 
------ ------
100.0 100.0 100.0 
Theophylline, lactose and povidone were blended together, passed 
through a 40 mesh screen and reblended for fifteen minutes using a "V" 
shell blender. The powder mix was placed in a 2.8 liter bowl and mixed 
five minutes using an instrumented Hobart mixer set at slow speed. The 
powder blend was wet granulated with 3A denatured alcohol by adding at a 
constant rate (35.3 ml/minute) while recording the relative torque on 
the paddle. Five phases of the torque profile were identified. Phase I, 
II, and III for each formulation were repeated and the wet granulations 
were dried at 5o0c for four hours in a forced hot air oven. Dried 
42 
granulations were sized through #18 mesh screen fitted to an oscillating 
granulator. These granulations were studied for all the physical 
parameters. 
Ac-Di-Sol was added to the granulations, blended ten minutes using 
the Turbula blender, added lubricant and blended five minutes. Tablets 
were compressed on an instrumented Stokes B2 rotary tablet press. Tablet 
weight and compression force were set at 135 mg and 4 KN respectively. 
These tablets were tested for all the parameters listed in the tablet 
characterization section. 
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TABLE VII 
Hydrochlorothiazide formulations with soluble and insoluble matrices 
Formulations 
12 13 
Ingredients % weight per tablet 
Hydrochlorothiazide 9.7 9.7 
Mannitol 82.4 
Di calcium phosphate anhydrous 82.9 
Povidone C-30 4.9 4.9 
Ac-Di-Sol 2.0 2.0 
Magnesium stearate 1.0 0.5 
------
100.0 100.0 
The same manufacturing procedure was used as for the theophylline 
formulations, except water was used as granulating fluid and added at a 
rate of 40 ml/minute. Granulations were studied for their physical 
properties. Mannitol tablets were compressed at 2.2 KN and dicalcium 
phosphate tablets at 6.4 KN. These tablets were studied for their 
physical parameters listed in tablet characterization section. 
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Trial 
1 
2 
3 
4 
5 
TABLE VIII 
Experimental design I - Formulation variables (independent) 
A - Binder 1. Povidone C-30 
2. Methyl cellulose 15LV (methocel) 
3. Hydroxypropyl cellulose (Klucel) 
B - Binder concentration 1. 3 % 
2. 6 % 
C - Granulating fluid 1. Water 
2. 3A denatured alcohol 
3. Isopropyl alcohol 
TABLE IX 
Experimental design - I (Factorial design) 
--- Factor level in experimental units ---
A 
1 
1 
1 
1 
1 
45 
B 
1 
1 
1 
1 
2 
c 
1 
1 
2 
3 
1 
( Table IX Continued -------
--- Factor level in experimental units ---
Trial A B c 
6 1 2 2 
7 1 2 3 
8 1 2 3 
9 2 1 1 
10 2 1 2 
11 2 1 3 
12 2 2 1 
( 13 2 2 2 
14 2 2 3 
15 3 1 1 
16 3 1 1 
17 3 1 2 
18 3 1 3 
19 3 2 1 
20 3 2 2 
21 3 2 3 
22 3 2 3 
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Experimental design - I: Hydrochlorothiazide tablet formulations 
Ingredients 
Hydrochlorothiazide 
Binder 
Binder concentration 
Granulating fluid 
Dicalcium phosphate anhydrous 
Ac-Di-Sol 
Magnesium stearate 
% weight per tablet 
10.0 
A 
B 
c 
{87.5 - B) 
2.0 
0.5 
100.0 
In all the experiments in this design, the following factors were 
kept constant: drug level, disintegrant concentration, lubricant level, 
batch size, dry mixing time, rate of addition of granulating fluid, rate 
of mixing, drying temperature, moisture level after drying, screen used 
for sizing granulation after drying, tablet weight, compression force 
for final tableting and all the equipment used. 
Hydrochlorothiazide, binder and anhydrous dicalcium phosphate 
were mixed together for ten minutes. The powder mix was passed through a 
40 mesh screen and reblended fifteen minutes using a ''V" shell blender. 
This powder mix (1 kg} was mixed in a 2.8 liter Hobart bowl for five 
minutes at 145 RPM and then wet granulated using a specified granulating 
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fluid by adding at a constant rate (25.6 ml/minute) while recording the 
relative torque on the paddle. Five phases of the torque profile were 
identified and all experiments were repeated to the end of phase III. 
All twenty-two batches of wet granulations were dried at the same time 
in the same forced hot air tray dryer at so0c. Granulations were dried 
to less than 1% moisture level. 
To reach a 1% moisture level, drying times for wet granulations 
made with alcohol (3A ethanol or isopropanol) and with water required 
six and ten hours respectively. These dried granules were sized through 
#18 mesh screen fitted to an oscillating granulator. These granulations 
were tested for all the physical parameters. 
Ac-Di-Sol was added, blended fifteen minute, added lubricant and 
blended five minutes using the Turbula blender. Compression and ejection 
profiles were generated for each batch by keeping the tablet weight 
(200 mg) constant using the Stokes B2 instrumented rotary press. Four 
sets of 1/4 inch standard round concave tooling were used. Final tablets 
were compressed at 6 KN. The tablets were studied for all the parameters 
listed in the tablet characterization section. 
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Experimental design II - Formulation variables (independent) 
A. Disintegrant 0. Control (no disintegrant) 
1. Ac-Di-Sol 
2. Explotab 
3. Crospovidone 
4. Starch 1500 
B. Disintegrant concentration 0. 0 
1. 0.25 
2. 0.50 
3. 1.00 
4. 2.00 
( 5. 4.00 
C. % Intragranular disintegrant 1. 0 
2. 50 
3. 100 
( 
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Experimental design - II Factorial design 
Factor level in experimental units 
Trial A B c 
1 0 0 1 
2 0 0 1 
3 0 0 1 
4 1 1 1 
5 1 1 2 
6 1 1 3 
7 1 2 1 
( 8 1 2 2 
9 1 2 3 
10 1 3 1 
11 1 3 2 
12 1 3 3 
13 1 4 1 
14 1 4 2 
15 1 4 3 
16 1 5 1 
17 1 5 2 
18 1 5 3 
19 2 1 1 
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Table XII Continued----------
Experimental design - II Factorial design 
Factor level in experimental units 
Trial A B c 
20 2 1 2 
21 2 1 3 
22 2 2 1 
23 2 2 2 
24 2 2 3 
25 2 3 1 
26 2 3 2 
27 2 3 3 
28 2 4 1 
29 2 4 2 
30 2 4 3 
31 2 5 1 
32 2 5 2 
33 2 5 3 
34 3 1 1 
35 3 1 2 
36 3 1 3 
37 3 2 1 
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Table XII Continued----------
Experimental design - II Factorial design 
Factor level in experimental units 
Trial A B c 
38 3 2 2 
39 3 2 3 
40 3 3 1 
41 3 3 2 
42 3 3 3 
43 3 4 1 
44 3 4 2 
45 3 4 3 
46 3 5 1 
47 3 5 2 
48 3 5 3 
49 4 1 1 
50 4 1 2 
51 4 1 3 
52 4 2 1 
53 4 2 2 
54 4 2 3 
55 4 3 1 
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Experimental design - II Factorial design 
Factor level in experimental units 
Trial 
56 
57 
58 
59 
60 
61 
62 
63 
A B C 
4 
4 
4 
4 
4 
4 
4 
4 
53 
3 
3 
4 
4 
4 
5 
5 
5 
2 
3 
1 
2 
3 
1 
2 
3 
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TABLE XIII 
Experimental design - II Hydrochlorothiazide tablet formulations 
Ingredients % weight per tablet 
Hydrochlorothiazide 
Disintegrant 
Disintegrant concentration 
% Intragranular disintegrant 
Dicalcium phosphate anhydrous 
Povidone C-30 
Magnesium stearate 
10.0 
A 
B 
c 
(84.5 - B) 
5.0 
0.5 
100.0 
In all the experiments in this design, the following factors were 
kept constant: drug level, binder level, lubricant level, batch size, 
dry mixing time, wet mixing time, drying temperature and time, moisture 
level after drying, screen used for sizing granulation after drying, 
tablet weight, compression force and all the equipment used. 
Drug, povidone, dicalcium phosphate anhydrous, and disintegrant 
(with or without) were mixed together for ten minutes, passed through a 
40 mesh screen, and reblended fifteen minutes. This powder mix (1 kg) 
was mixed five more minutes in a 2.8 liter Hobart bowl and wet 
granulated with water by adding at a constant rate (38.3 ml/minute) 
while recording the relative torque on the paddl~. Five phases of torque 
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profile were identified for all the experiments and the experiments were 
repeated to phase III. Mixing time (four minutes) was kept constant but 
the rate of addition of water was varied (38 to 48 ml/minute). Wet 
granulations were dried at 5o0c in a forced hot air oven at the same 
time for ten hours. Dried granulations were sized through #18 mesh 
screen fitted to an oscillating granulator. These granulations were 
tested for all the physical parameters. 
Disintegrant was added, blended ten minutes using the Turbula 
blender, magnesium stearate was added and blended five minutes. Tablets 
were compressed using an instrumented Stokes B2 rotary press fitted with 
four sets of 1/4 inch standard round concave tooling. Tablet weight was 
set at 200mg and compression force at 3.4 KN. Tablets were tested for 
all the parameters listed in the tablet characterization section. 
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TABLE XIV 
Formulations with two different grades of lactose 
Formulation 
Ingredients 
Lactose 
Lactose anhydrous 
Povidone C-30 
14 
% weight per batch 
95.0 
5.0 
15 
95.0 
5.0 
Lactose and povidone were mixed for ten minutes, passed through a 
40 mesh screen, and reblended for fifteen minutes. This powder mix was 
charged to a 2.8 liter Hobart bowl and mixed for five minutes. The 
powder blend (1 kg) was wet granulated with water (300 g) by adding at a 
constant rate and recorded the torque as a function of time. The same 
procedure was used for the second formulation and the torque was 
recorded on the same chart paper, to compare one against the other. 
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TABLE XV 
Lactose formulations with different levels of sucrose 
Formulation 
Ingredient 
Lactose 
Sucrose 
16 
100 
0 
17 18 
% weight per tablet 
95 
5 
90 
10 
19 
80 
20 
Granular sucrose was milled through #000 plate (0.020 1nch 
opening) fitted to a Fitzpatrick model M comminuting mill, hammers 
forward and high speed. Lactose and sucrose were blended together, 
passed through a 40 mesh screen and reblended for fifteen minutes. The 
powder mix (500 g) was wet granulated using the slow speed of the Hobart 
mixer by adding water (150 g) at a constant rate while recording the 
torque (mv). The same procedure was used for all the formulations and 
the torque profiles were recorded. These torque profiles were cut and 
pasted one on top of the other, to show the effect of soluble material 
on the wet granulation process. 
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TABLE XVI 
Lactose formulations with different levels of Avicel PH 101 
Formulation 
Ingredients 
Lactose 
Avicel PH 101 
20 
95 
5 
21 
% weight per batch 
90 
10 
22 
80 
20 
The same blending procedure was used as in previous formulations. 
The powder blends (500 g each) were wet granulated with ten percent W/W 
solution of povidone in denatured alcohol (150 g) and the torque on the 
paddle was recorded for each formulation. These torque profiles were cut 
and pasted one on top of the other, to show the effect of Avicel on 
lactose formulations in the wet granulation process. 
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TABLE XVII 
Granulation of lactose with different rates of mixing 
Formulation 
Ingredients 
Lactose 
10% W/W Povidone/denatured alcohol 
solution 
Mixing rate (rpm) 
100 
(30) 
23 
% weight per batch 
145 (slow speed) 
100 
(30) 
258 (medium) 
Lactose was wet granulated with ten percent W/W solution of 
povidone in denatured alcohol using the slow speed of the instrumented 
Hobart mixer, and the torque on the paddle was recorded. The same 
procedure was repeated using the medium speed of the instrumented mixer 
and the torque on the paddle was recorded on the same chart paper, to 
show the effect of mixing rate on the wet granulation process. 
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III. RESULTS AND DISCUSSION 
In the past relatively little attention has been given to the 
method of liquid addition in the wet granulation process. Normally, the 
binder solution is either poured into the bowl within a short time or 
aliquots of solution are added at fixed intervals (71-91). The factor 
having perhaps the largest effect on mean granule size is the mesh size 
of the screen used to wet granulate. In these methods, subjective 
judgement is involved in every stage of the process, such as, selecting 
the amount of granulating fluid, duration of kneading, and screen size 
to wet granulate. The literature is often conflicting as to the effects 
of processing and formulation variables on the properties of granules 
and the present state of useful knowledge is approximately zero. 
In this study, granulating fluid was added at a slow constant rate 
while recording the torque on the paddle of the instrumented Hobart 
mixer. This procedure allows uniform wetting of powder particles. The 
amount of granulating fluid added at any time point can be quantified. 
In addition, it also allows to study the changes of the torque values on 
the paddle as a function of granulating fluid and mixing time. The 
instrumentation of the mixer reported in this study is cheap and 
covenient. All the parts used in this instrumentation are commercially 
available. 
Formulation 1 (Table I) was used to test the reproducibility of 
the data generated by the instrumented Hobart mixer. Figure 3 shows, 
that the output from the triplicate experiments using formulation 1 were 
plotted on the same chart paper, one above the other. The base line of 
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plots one and two were adjusted by subtracting 200 and 100 mv 
respectively. Mean and relative standard deviation (Table XVIII) of the 
torque values indicate that the data were reproducible. The maximum 
relative standard deviation was less than two percent. 
After switching on the instrumented mixer, a certain time (less 
than two minutes) is needed to reach steady state torque values without 
any load on the paddle. This phenomenon is due to the viscosity changes 
of the lubricant (grease) in the transmission case unit. To avoid this 
problem, all the dry powder blends were mixed for five minutes before 
starting the addition of granulation fluid. 
Ideally, in designing the equipment one would prefer to have the 
torque-measuring sensor as close as possible to the place where the 
granulation process is occurring. If the absolute work done during the 
process of agglomeration were of concern, this equipment would not be 
suitable. The torque (mv) output generated by this equipment is relative 
to the actual torque applied on the paddle rather than absolute due to 
the location of measuring equipment. However, in this investigation we 
were interested only in the relative changes in torque occurring during 
the addition of granulating fluid. In the mixing process, changes in 
torque occur as a result of the change in the cohesive force or of the 
tensile strength of the agglomerates in the moistened powder bed. 
The shape of the torque profile seems to be similar to the power 
consumption profile reported by Leuenberger (39) using the same type of 
formulation. A power - torque relationship is as follows (92): This 
relationship is derived from the fact that power is simply as the rate 
of doing work. Power P is the derivative of work with respect to time or 
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Fonnulation I : Torque - Time Profile 
Torque (mv) 
Time (sec) Trial 1 2 3 X (mv) R.S.D 
------------------------------------------------------------------------
0 240 238 240 239.33 0.48 
20 250 252 248 250.00 0.80 
40 260 258 258 258.67 0.45 
60 255 255 260 256.67 1.12 
80 260 258 260 259.33 0.45 
100 260 260 260 260.00 0.00 
120 270 272 270 270.67 0.43 
( 140 280 281 280 280.33 0.21 
160 310 312 310 310.67 0.37 
180 370 375 370 371. 67 0.78 
200 450 455 450 451. 67 0.64 
220 500 495 495 496.67 0.58 
240 530 540 550 540.00 1.85 
260 520 525 530 525.00 0.95 
280 575 570 570 571. 67 0.50 
300 580 582 590 584.00 0.91 
320 620 625 620 621. 67 0.46 
340 720 725 720 721.67 0.40 
( 
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p = dW I dt = 2 TI T. RPM 
and 
T = p I 2 TI • RPM 
Horse Power HP or the rate of doing work is defined by: 
1 HP = 550 lb. ft. I sec. = 33000 lb. ft. I min. 
We, therfore have the following convenient relations 
also 
T = (33000 . HP I 2 TI • RPM) lb.ft. 
T = (5252 . HP / RPM) lb. ft. 
1 Watt = 44.167 lb. ft. I min. 
Therefore, we also have the relations that 
T = (7.03 . Watt I RPM) lb. ft. 
Power consumption (watt) = (T . RPM I 7.03) lb. ft. I min. 
For a syncronous motor, power consumption is directly proportional to 
torque. 
Figure 4 shows a typical torque profile. The curve can be divided 
into five distinct phases, in relation to the quantity of the 
granulating fluid added. In the first phase, the powder mix is moistened 
without any observable increase in the torque value, which remains the 
same as in the dry powder mixing phase. In this phase, the drops of 
granulating fluid contact the dry powder mix and the powder forms 
agglomerates. The surface of these agglomerates and the remaining powder 
mix was dry. In phase two of the process, the surface of the charge was 
still dry but the powder balls were broken by shearing and compacting 
forces. Torque on the paddle increases sharply, to an extent dependent 
on the granulate composition, and the solid particles begin to 
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agglomerate. During the third phase torque levels off. The surface of 
the solid particles was wet and further agglomeration was observed. At 
the end of the phase three all the granules were wet and shiny. In phase 
four torque increases and reaches a maximum. In this phase the wet 
granules stick together, grow uncontrolably and finally become a pasty 
mass. During the fifth phase, torque falls steeply, and the pasty mass, 
which is still firm in the fourth phase, breaks down and slowly passes 
into a suspension. These five phases were obtained with practically all 
types of powder blends investigated except microcrystalline cellulose. 
For this system it is possible that the granulation fluid diffuses into 
the inner pores and leaves the surface dry in the microcrystalline 
cellulose powder blends. In general, volume of liquid phase present at 
the surface of the solid particles during the processing is one of the 
most important factors governing the degree of agglomeration (33). 
The physical properties of the raw materials used in this study 
are recorded in the tables XIX - XXII. Experimental results of 
theophylline, phenytoin and acetaminophen solubility in water at twenty 
five degrees centigrade are in agreement with the results reported in 
the literature (93-95). 
The lactose matrix formulations were investigated with 
theophylline, phenylpropanolamine or hydrochlorothiazide as drugs at ten 
percent level. Physical properties of each drug system were different. 
In these experiments, all the formulation and processing variables were 
kept constant except the type of the drug in the formulation (Table II). 
The torque profiles of these formulations contained all five phases 
reported earlier. Torque profiles of theophylline and phenypropanolamine 
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TABLE XX 
Percent Particle Size Distribution of Raw Materials 
Size (µm) Theophylline Phenytoin PPA HTZ APAP 
------------------------------------------------------------------------------
0 - 44 3.0 0.0 
44 - 74 15.7 1. 2 
74 - 105 31. 3 14.7 
105 - 149 31. 5 39.4 
149 - 177 14.9 37.8 
177 - 250 3.5 3. 7 
250 - 420 0.0 3. 1 
PPA = Phenylpropanolamine Hydrochloride 
HTZ = Hydrochlorothiazide 
APAP = Acetaminophen 
4.5 10.0 0.4 
16.9 1 9 . 7 4.7 
30.0 33.3 12.8 
24.8 36.2 2 7. 7 
13.0 0.4 23.0 
9. 1 0.0 20. 1 
1. 7 0.4 11. 3 
~ 
,,.-....._ 
--
TABLE XIX 
Percent Particle Size Distribution of Raw Materials 
Size ( µm) Lactose Lactose Di calcium Mannitol 
hydrous anhydrous Phosphate anh. 
------------------------------------------------------------------------------
0 - 44 2.8 0.4 32.6 6. 7 
44 - 74 25.6 23.0 24.4 16.6 
74 - 105 59.4 11. 2 24.5 28.9 
"(j\ 105 - 149 11. 7 16.6 12.7 18.9 00 
149 - 177 0.4 9.8 4.2 16.9 
177 - 250 0.0 23.6 1. 2 6.1 
250 - 420 0.0 15.4 0.3 6.0 
( TABLE XXI 
Bulk Properties of Raw Materials 
Density 
Loose Tapped % Compressibility 
(g/cm3) (g/cm3) 
Theophylline anh. 0.474 0.752 37.0 
Phenytoin 0.390 0.765 49.0 
Phenylpropanolamine HCl 0.355 0.703 49.5 
Hydrochlorothiazide 0.533 0.973 45.2 
Acetaminophen 0.357 0.822 56.6 
Lactose hydrous 0.508 0.847 40.0 
Lactose anhydrous 0.565 0.787 28.2 
Dicalcium Phosphate anh. 0.983 1. 720 42.8 
Mannitol 0.379 0.690 45.1 
% Compressibility= ( Tapped bulk density - loose bulk density )/ 
Tapped bulk density X 100 
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TABLE XXII 
Solubility and Cohesiveness of Drugs used in this Study 
Solubility in Water at 250C 
Drug mg I ml 
Theophylline anhydrous 8.0 (Ref. 93) 
Phenytoin 0.0143 (Ref. 94) 
Phenylpropanolamine hydrochloride 390.0 
Hydrochlorothiazide 1.29 
Acetaminophen 15.0 (Ref. 95) 
* Reference 68 
70 
* Cohesiveness 
% 
54.0 
31.0 
10.0 
62.0 
21.0 
( 
( 
formulations (Fig. 5) show that condensation of phase II and III was 
seen for the phenylpropanolamine formulation compared with the 
theophylline formulation. This can be explained by the good wettability 
and solubility of the phenylpropanolamine. Hardesty reported (33,34), 
that the moisture requirement for agglomeration decreases linearly with 
increasing proportion of salt in the granulation liquid. This suggests a 
possible relationship between the solubility of the solid phase in the 
granulation fluid and its tendency to decrease the moisture requirement 
for optimum agglomeration. 
Scanning electron micrographs (Fig's. 6-9) of the theophylline and 
phenypropanolamine system show the nuclei for agglomeration were formed 
in phase I of the process. These photographs indicate that the powder 
was agglomerated and increased in size with the increase in addition of 
granulation fluid and mixing time. These photographs also indicate that 
the small powder particles decreased while the coarser fractions 
increased. The shape and structure of the agglomerates indicate that the 
granule growth is due to a coalescence mechanism for these formulations 
which were granulated using a planetary mixer. 
Particle size distributions of granulation (after sizing) of the 
formulations 2 thru 4 show, an increase in median particle size from 
phase I to II and also from phase II to III (Fig's. 10,11 and Table 
XXIII). Although, scanning electron microscopy showed an increase in 
particle size from phase II to III for phenylpropanolamine formulation, 
there was no difference after sizing the granulation (Fig's. 9 and 11). 
Particle size distributions of phenytoin and acetaminophen granulations 
(Tables XXV and XXIX) show data which follow the same pattern as in 
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FIGURE 7 
Scanning electron micrographs of theophylline formulations 
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FIGURE 8 
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FIGURE 10 
Particle size distribution of theophylline granulations 
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( theophylline and hydrochlorothiazide formulations. In general, it can be 
concluded that mean granule size increases as the volume of the 
granulating fluid is increased and mixing time is increased. 
Granulation flow property is one of the most important factors 
which affects the final properties of tablets. Flow properties of the 
formulation 2 thru 5 and 7 is shown in Figures 13 and 14. A significant 
increase in flow rate from the powder blend before granulation to phase 
I granulation and also from phase I to II granulations is apparent. 
There is no significant difference between phase II and III 
granulations, except for the phenytoin granulation (Fig's. 13 and 14). 
Figure 12 shows the effect of sizing the theophylline granulation with 
two types of equipment. The flow rate of granulation sized through # 18 
mesh screen (fitted to an oscillating granulator) was slightly better 
than the granulation sized through# 2 plate, (fitted to a Fitz mill), 
but it is not statistically significant. 
Bulk properties of granulations from formulations 2 thru 4 and 7 
showed (Fig's. 15,16 and Tables XXIV,XXX) that the granulation goes 
through a stage of decreased bulk density due to a loosely held 
agglomerates. Phase II granules of these formulations showed a minimum 
loose and tapped bulk density compared to other granules. In the case of 
phenytoin granulations, bulk density increased with increased addition 
of granulating fluid and mixing time. In general, the powder particles 
randomly collide with each other in the presence of binding liquid and 
mixing, forms loose aggregates, these loose aggregates densify with 
further addition of liquid and mixing. Percent compressibility values 
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Formulations 5 and 7: Granulations flow profile 
150 
-
u 
l.JJ 
en 
......... 
en 
~ ( <!> 
_.. 
UJ 
I-
<t 
a:: 
~ 
0 
..J 
LL. 
I SEM 
0 1 2 3 
PHASE OF THE WET GRANULATION PROCESS 
0 PHENYTOIN 0 ACETAMINOPHEN 
82 
( 
1.0 
-
.., 
.75 E 
~ 
"' E 
~ 
... 
s 
> !:::: 
"" z w 
.50 c 
~ 
...I 
:::> 
al 
.25 
0 
( 
FIGURE 15 
Formulation 2: Granule bulk profile 
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Formulation 3: Granule bulk profile 
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TABLE XXIII 
Percent Particle Size Distribution of Hydrochlorothiazide Granulations 
Phase of the Wet Granulation Process 
Size (µm) I I I I I I v 
0 - 74 5. 7 3.0 6. 1 13.0 
74 - 149 31.1 32.6 31. 2 22.9 
00 149 - 177 14.1 12.8 11. 4 4.3 
U1 
177 - 250 13.0 12.4 11.1 7. 0 
250 - 420 25.3 27.7 25.2 23.0 
420 - 840 10.8 11. 4 15. 1 29.7 
840 - 1000 0.0 0.0 0.0 0. 1 
( TABLE XXIV 
Granulation and Tablet Properties of Hydrochlorothiazide Formulation 
Phase of the Wet Granulation Rrocess 
I I I II I v 
------------------------------------------------------------------------
Flow Rate x 99.35 117. 58 114.09 94.12 
(g/s,ec) S.D 1.13 8.25 8.59 7.12 
Linearity 18.9 19.2 19.2 18.5 
Bulk Density (g/cm3) 
Loose 0.514 0.508 0.520 0.598 
Tapped 0.734 0.700 0.754 0.968 
% Compressibility 30.00 27.43 31.00 38.22 
Tablet Weight x 136.0 141.2 140.9 141.3 
(mg) S.D 2.0 1.2 1. 3 2.6 
( Hardness x 6.20 7.13 7. 72 8.08 (kg) S.D 0.55 0. 77 0.63 1.03 
Fri ability (% loss) 0.75 0.08 0.15 0.14 
Disintegration x 6.47 9.67 10.08 8.07 
(minutes) S.D 1.03 0.74 0.59 1.10 
Linearity= ( r 2 - 0.8 ) X 100 r 2 = Coefficent of determination 
Compression Force: 10 KN 
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TABLE XXV 
Percent Particle Size Distribution of Phenytoin Granulations 
Phase of the Wet Granulation Process 
Size (µm) I II I I I IV v 
----------------------------------------------------------------------------
0 - 74 0.8 1. 2 1. 4 8.4 11. 4 
74 - 105 8. 5 6.0 4.2 16. 3 15. 1 
co 105 - 149 14.3 11. 5 6.2 15. 1 23.7 
-.....J 
149 - 250 24.9 23.1 8.2 8.0 11. 2 
250 - 420 22.7 21. 5 12.0 5.4 6.4 
420 - 840 17. 3 20.1 25.2 10.2 10.6 
840 - 1000 11. 5 16. 5 42.8 36.5 21. 5 
(X) 
(X) 
,--....,. 
TABLE XXVl. 
Granulation Properties of Phenytoin Formulations 
Phase of the Wet Granulation Process 
--------------------------------------------------------------
I 
% Granulating fluid/ 8.72/150 
Mixing time (sec) 
Flow Rate x 124.50 
( g/.sec) S.D 0.87 
Linearity 19.20 
Bulk D3nsity ( g/ cm ) 
Loose 0.463 
Tapped 0.625 
% Compressibility 25.90 
Linearity= ( r 2 - 0.8 ) X 100 
r
2 
= Coefficent of determination 
* B = Blocked 
I I 
11.16/192 
139.00 
3.90 
19.60 
0.481 
0.641 
25.00 
I I I IV v 
19.19/330 26.83/462 30.00/516 
* * 179.80 B B 
6.63 
19.60 0 0 
0.555 0.625 0.595 
0.676 0.862 0.862 
17.90 27.50 31. 00 
,..--..,._ 
( TABLE XXVII 
Tablet Properties of Phenytoin Formulations 
Phase of the Wet Granulation Process 
I I I II I 
Compression Force x 7202 7276 7322 
(Newtons) S.D 532 414 493 
Ejection Force x 449 458 432 
(Newtons) S.D 41 33 26 
Weight (mg) x 249.30 251.00 248.50 
S.D 3.32 3.74 3.20 
Thickness (inches) x 0.140 0.141 0.139 
S.D 0.001 0.001 0.001 
Hardness (kg) . x 4.70 4.90 4.70 
( S. D 0.19 0.47 0.42 
Friability (%loss) 0.30 0.22 0.34 
Disintegration x 8.17 7.84 9.29 (minutes) S.D 0.52 0.85 0.99 
( 89 
( TABLE XXVIII 
Tablet Properties of Phenytoin Formulations (with Starch 1500) 
Phase of the Wet Granulation Process 
I II I I I 
Compression Force x 7049 7311 7137 
(Newtons) S.D 329 620 610 
Ejection Force x 373 404 376 
(Newtons) S.D 43 44 25 
Weight (mg) x 275.50 279.5 273.8 
S.D 3.72 2.88 3.43 
Thickness (inches) x 0.153 0.155 0.152 
S.D 0.001 0.001 0.001 
Hardness (kg) x 3.20 3.00 3.10 
S.D 0.18 0.05 0.08 
( Friability (% loss) 0.31 0.25 0.20 
Disintegration x 6.82 8.46 8.89 
(minutes) S.D 0.34 0.66 0.73 
90 
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TABLE XXIX 
Percent Particle Size Distribution of Acetaminophen Granulations 
Phase of the Wet Granulation Process 
Size (µm) I I I I I I v 
0 - 74 0.1 0.0 0.2 0.2 
74 - 105 0.4 0.2 0.5 0.4 
105 - 149 1. 1 1.1 0.9 5.9 
\D 
...... 
149 - 250 7. 3 6.4 2.3 10.4 
250 - 420 41. 7 27.7 8.5 15.9 
420 - 840 29.6 41. 2 44.0 12.0 
840 - 1000 19.9 23.5 43.6 55.3 
,,..-. 
~ 
N 
~ 
TABLE XXX 
Granulation Properties of Acetaminophen Formulations 
Phase of the Wet Granulation process 
Flow Rate 
(g/sec) 
Linearity 
x 
S.D 
Bulk gensity 
( g I cm ) 
Loose 
Tapped 
% Compressibility 
I 
114.5 
3.3 
19.2 
0.456 
0.585 
22.1 
Linearity= ( r 2 - 0.8 ) X 100 
r 2 = Coefficent of determination 
* B = Blocked 
I I 
141. 5 
1. 2 
19. 6 
0.458 
0.533 
14.1 
I I I 
145.6 
1. 3 
19.6 
0.510 
0.578 
11. 8 
v 
* B 
0 
0.550 
0.794 
30.7 
--..... 
,..--. ,.....--.._ ~ 
TABLE XXXI 
Tablet Properties of Acetaminophen Formulations 
Phase of the ~et Granulation Process 
I I I I II 
Compression Force x 16294 16452 16098 
(Newtons) S.D 395 795 649 
Ejection Force x 160 189 183 
(Newtons) S.D 23 9 19 
Weight (mg) x 466.0 464.0 472.0 
l.O S.D 3. 2 2.4 3.8 w 
Thickness (inches) x 0.196 0.196 0.197 
S.D 0.001 0.001 0.001 
Hardness (kg) x 4.00 4.53 4.98 
S.D 0.52 0.32 0.23 
Friability (%loss) 0.83 0.64 0.69 
Disintegration x 0.93 2.47 4.76 
(minutes) S.D 0.08 0.43 0.23 
( 
( 
calculated from bulk density values showed a good correlation with 
flowability of the granulation measured by Recording Powder Flowmeter. 
Granulations from formulations 2 thru 4 were tableted at 10 KN 
compression force using 1/4 inch standard round concave tooling. The 
tablet hardness is shown in figures 17 and 18 as a function of wet 
mixing time and phase of the wet granulation process. Tablet hardness 
was increased with increased addition of granulating fluid and wet 
mixing time {Fig's. 17, 18 and Table XXIV). Disintegration time of these 
tablets was directly proportional to the hardness {Fig. 19 and Table 
XXIV). Dissolution profiles of these formulations {Fig's. 20 and 21) 
indicate no difference between the tablets made from granulations from 
different phases. Tablet data for phenytoin and acetaminophen are shown 
in Tables XXVII, XXVIII and XXXI. Phenytoin tablets from phase I to III 
were compared with Parke-Davis tablet and the 8-cyclodextrin-drug 
complex tablet for the 
rate of dissolution (Fig. 22). There was no difference in dissolution 
rate between phase I to III tablets. The dissolution rate of phase I to 
III tablets were significantly better than the commercially available 
Parke-Davis tablet and significantly slower than the .B-cyclodextrin-drug 
complex tablet. The dissolution rate of phase III tablets with and 
without starch 1500 is shown in Figure 23. Acetaminophen tablet 
dissolution data are shown in Figure 24. 
Phenylpropanolamine and theophylline formulations (Table II) were 
used to test the effect of extended mixing on the wet granulations after 
discontinuing the addition of granulating fluid. Figures 25 thru 27 show 
the particle size distribution of phenylpropanolamine phase I to III 
94 
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Formulation 3: Tablet hardness as a function of wet mixing ti me 
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Formulations 2 and 3: 
Disintegration time as a function hardness 
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Acetaminophen tablet dissolution profile 
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particle si ze dist r ibution of phase 3 gr anu l ati ons 
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granulations. Mean particle size was decreased in all cases with 
increased mixing time. Phase I and II granulations were more sensitive 
to mixing in the first ten minutes compared to the later ten minutes. 
Phase III granulations were also decreased in mean particle size, but 
these systems were not as sensitive as phase I and II granulations. Flow 
properties (Fig's. 28-30) of these granulations reflected the mean 
particle size of granulations. The flow rate seems to decrease with 
increased wet mixing, but it is not statistically significant. Bulk 
density (Fig. 31) of the granulations was increased with extended wet 
mixing irrespective of the amount of granulating fluid used. 
Figures 32 thru 34 show the particle size distributions of Phase I 
to III of theophylline formulation. Mean particle size was decreased in 
the case of phase I and II granulations and particle size was increased 
in phase III with extended wet mixing. Phase II granulations were 
decreased in mean particle size but they were not as sensitive as phase 
I granulations. These data indicate that the amount of granulation fluid 
has a direct effect on the particle size distribution in the case of 
extended wet mixing also. Extended mixing of granulations from phase I 
and II has no significant effect on the flow rate (Fig's. 35 and 36) of 
these granulations. Phase III granulations of theophylline formulations 
increased mean particle size and flow properties (Fig. 37) with extended 
wet mixing to twenty minutes. Bulk density (Fig's. 38-40) of the phase I 
and II granulations was increased and phase III granulations was 
decreased with extended wet mixing. In general, we can conclude that the 
formulations containing more soluble material are more sensitive to the 
amount of granulating fluid and also extended wet mixing. 
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FIG URE 28 
Effect of extended mixing on 
flow rate of phase 1 granulations 
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FIGURE 29 
Effect of extended mixing on 
. 
flow rate of phase 2 granulations 
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FIGURE 31 
Effect of extended mixing on 
bulk properties of phase 1, 2 and 3 granulations 
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Effect of extended mixing on 
particle size distribution of phase 1 granulations 
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Effect of extende d mi x ing on 
particle si ze dis tr ibution of ph as e 2 gr anulations 
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FIGURE 34 
Effect of extended mixing on 
particle size distribution of phase 3 granulations 
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FIGURE 35 
Effect of extended mixing on 
flow rate of phase 1 granulations 
THEOPHYLLINE FORMULATION 
200 '1 4.3% Granulating Fluid 
150 
I 
100 
50 
100 400 
1 
600 800 
MIXING TIME (seconds) . 
l l 4 
! 
Mixing Time 
• 100 Seconds 
• 600 Seconds 
o 1200 Seconds 
I SEM 
1200· 
-u 
Cl) 
Ul 
-Ul 
E 
al 
... 
( s w 
I-
< cc: 
3: 
0 
..I 
LL 
( 
FlGURE 36 
Effect of extended mixing on 
flow rate of phase 2 granulations 
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Effect of extended mi~tng on 
flow rate of phase 3 granulation~ 
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FIGURE 38 
Effect of extended mixing on 
bulk properties of phase 1 granulations 
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FIGURE 39 
Effect of extended mixing on 
bulk properties of phase 2 granulations 
THEOPHYLLINE FORMULATION 
1.00 · 9.43% Granulating Fluid 
0.75! 
.... 
0.50 ' 
0.25 
0 220 400 600 800 
MIXING TIME (seconds) 
11 8 
Tapped 
Loose 
-0 
Mixing Time 
• 220 Seconds 
• 600 Seconds 
o 1200 Seconds 
1200 
-
... 
E 
~ 
I/) 
E 
ft! 
( ... s 
> I-
iii 
z 
w Q 
::.::: 
_, 
::> 
m 
FIGURE 40 
Effect of extended mixing on 
bulk properties of phase 3 granulations 
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Formulations (Table VI) containing different levels of 
theophylline were used to find the effect of concentration of drug on 
the wet granulation process. The torque profiles of these formulations 
contained all five distinct phases. The particle size distribution of 
phase I to III of these formulations is shown in Figures 41 thru 43. 
These figures indicate that the higher the concentration of drug in the 
formulation the smaller the mean particle size in phase I to III of the 
granulation process. Although, the higher drug concentration in the 
formulation produced smaller mean particle size in phase III, but the 
difference in granule size is very small between 40% and 75% drug 
formulations. Flow properties of the granulations from phase I to III of 
formulations 9 thru 11 are shown in Figure 44. These flow data indicate 
that phase III of the granulation process is the optimum with respect to 
the amount of granulating fluid and mixing time needed for the wet 
granulation process, irrespective of the concentration of drug in the 
formulation. Percent compressibility data calculated from bulk densities 
are shown in Figure 45. Tablet properties of formulations 9 thru 11 are 
recorded in Tables XXXII thru XXXIV. Tablet weight variation data and 
compression force data directly correlate with the granulations flow 
properties. Tablets compressed from granulations with poor flow 
properties showed higher standard deviation from mean of tablet weight 
and compressional force. These data support the well-recognized fact 
that the quality of the tablets is dependent upon the quality of the 
granulations used in the manufacture of final product. Tablet 
disintegration data indicate that when the concentration of theophylline 
was raised, an increase in disintegration time was observed. 
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FIGURE 4-1 
Theophylline formulations 9 - 11: 
Particle size distribution of phase granulati_ons 
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FIGURE 42 
Theophylline formulations 9 - 11: 
Particle size distribution of phase 2 granulations 
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FIGURE 43 
Theoohylline formulations 9 - 11: 
Particle size distribution of phase 3 granulations 
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FIGURE 44 
Theophylline formulations 9 - 11: Granulations flow profiles 
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Theophylline for mulations 9 - 11: 
Percent compressibility as a function of phase 
of the wet ranulation process 
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( TABLE XXXII 
Theophylline Formulations (Granule and Tablet Properties) 
Phase I 
--------------------------------------
Formulation 9 10 11 
------------------------------------------------------------------------
W/W Granulating fluid/ 4.3/90 4.3/90 2.8/59 
Mixing time (sec) 
Linearity 18.9 
Bulk Density (g/cm3) 
Loose 0.514 0.486 0.452 
Tapped 0.657 0.748 0.753 
% Compressibility 21.8 35.0 40.0 
Compression Force x 3948 4013 3937 
( (Newtons) S.D 136 467 528 
Ejection Force x 202 212 157 
(Newtons) S.D 59 70 43 
Weight x 132.6 137.0 135.6 
(mg) S.D 1.6 7.4 14.8 
Hardness x 4.4 4.4 5.9 
{kg) S.D 0.3 0.4 0.8 
Fri ability (% loss) 0.08 0.13 0.04 
Disintegration x 4.44 9.50 9.40 
(minutes) S.D 0.26 0.45 3.80 
l 26 
( TABLE XXXIII 
Theophylline Formulations (Granule and Tablet Properties) 
Phase II 
--------------------------------------Formulation 9 10 11 
------------------------------------------------------------------------
W/W Granulating fluid/ 9.4/197 10.4/218 8.1/170 
Mixing time (sec) 
Linearity 19.5 19.3 
Bulk Density (g/cm3) 
Loose 0.484 0.463 0.358 
Tapped 0.630 0.649 0.551 
% Compressibility 23.2 28.7 35.0 
Compression Force x 3999 4050 4097 
( (Newtons) S.D 116 124 479 
Ejection Force x 188 162 104 
(Newtons) S.D 33 4 3 
Weight x 132.6 131.4 136.3 
(mg) S.D 1.4 1.3 7.8 
Hardness x 6.1 6.5 8.0 
(kg) S.D 0.7 0.4 0.5 
Fri ability (% loss) 0.08 0.00 0.00 
Disintegration x 7 .10 16.80 26.25 
(minutes) S.D 0.49 0.68 1.33 
( l 2 7 
( TABLE XXXIV 
Theophylline Formulations (Granule and Tablet Properties) 
Phase II I 
--------------------------------------Formulation 9 10 11 
------------------------------------------------------------------------
W/W Granulating fluid/ 16.3/273 21. 7 /363 20.7/347 
Mixing time (sec) 
Linearity 19.4 19.3 19.3 
Bulk Density (g/cm3) 
Loose 0.480 0.548 0.433 
Tapped 0.629 0. 774 0.623 
% Compressibility 23.7 29.2 30.5 
Compression Force x 3974 3909 4064 
( (Newtons) S.D 167 126 211 
Ejection Force x 176 198 140 
(Newtons) S.D 15 40 32 
Weight x 135.9 136.0 135.0 
(mg) S.D 1.4 1.0 0.7 
Hardness x 7.3 5.8 7.1 
(kg) S.D 0.8 0.6 0.4 
Friability (% loss) 0.00 0.04 0.01 
Disintegration x 11. 63 18.60 34.50 
(minutes) S.D 0.26 0.38 1.05 
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Formulations 12 and 13 (Table VII) were used to study the effect 
of matrices (soluble or insoluble) on the wet granulation process. 
Figure 46 shows the torque-time profile of formulation containing 
soluble mannitol matrix. It contains all five distinct phases reported 
earlier with lactose matrix, but the torque in phase III did not level 
off. The torque in phase III was increased with the addition of 
granulation fluid. For highly soluble systems it is possible that the 
porosity of the solid material collapses and leaves the surface of the 
material wet. This phenemenon may be causing rapid agglomeration and 
also increased cohesiveness between the granules. Figure 47 shows the 
torque time profile of formulation containing insoluble dicalcium 
phosphate matrix. This torque profile contained all five phases reported 
earlier. The particle size distribution of phase I to III of formulation 
12 and 13 are shown in Figure 48. In both formulations the mean particle 
size increases with increased addition of granulating fluid and mixing 
time. The mannitol formulations produced finer granules compared to the 
dicalcium phosphate formulations in every phase of the wet granulation 
process. Figure 49 shows the effect of mannitol and dicalcium phosphate 
on the flow properties of granulations produced at phase I to III. The 
dicalcium phosphate matrix produced significantly (P < 0.05) better 
granulations at every phase of the granulation. Flow rate of dicalcium 
phosphate granulations from phase I to III showed no significant (P < 
0.05) difference. The mannitol matrix granulation showed a significant 
difference (P < 0.05) in flow rate between each phase. Percent 
compressibility data support the granulation flow data (Figure 50). The 
results of granule and tablet properties of hydrochlorothiazide 
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FIGURE 46 
Torque - time profile 
Hydrochlorothiazide formulation with mannitol matrix 
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FIGURE 47 
Torque - time profile 
Hydrochlorothiazide formulation with dicalcium phosohate matrix 
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FIGURE 48 
Hydrochlorothiazide formulations with mannitol or dicalcium 
phosphate matrix: Particle size distribution of phase l - 3 
granulations 
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FIGURE 49 
Hydrochlorothiazide formulations wit~ mannitol or di.calcium 
phosphate matrix: Granulations flow profile 
-(,) CP 
.!!! 
s 
w 
I-
< 
200 
150 
a: 100 
;: 
0 
...J 
u. 
50 
•Mannltol Formulation 
oDicalcium Phosphate Formulation 
1 2 
PHASE OF THE WET GRANULATION PROCESS 
l 3 3 
3 
( 
FIGURE 50 
Hydrochlorothiazide formulations with mannitol or dicalcium 
phosphate matrix: Percent compressibility as a function of 
the wet granulation process 
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formulations with soluble or insoluble drug are recorded in the Table 
XXXV. The mannitol formulations needed a higher level (1.0%) of 
magnesium stearate as lubricant to compress tablets. Due to the elastic 
nature of the mannitol matrix, satisfactory tablets were formed at a 
very narrow compressional force range. The tablets were capped at higher 
compressional force and softer tablets were produced below 2KN force. 
Because of the granulation density difference between mannitol and 
dicalcium phosphate matrices, tablets with different weights were 
manufactured using the same size tooling. Although, it is not possible 
to compare directly one tablet against the other, these tablet physical 
properties gave sufficient information to generalise the 
effects of the matrices on the granulation process. The dicalcium 
phosphate matrix produced significantly better flowable and compressible 
granulation than the mannitol matrix at every phase of the wet 
granulation process. The results of tablet dissolution (Table XXXV) show 
no significant difference between the formulations at every phase of the 
process. 
Based on the data so far, (four different drugs with lactose 
matrix, hydrochlorothiazide with dicalcium phosphate and mannitol 
matrices) it can be seen granulations from phase III showed optimum flow 
and compression characteristics, irrespective of the concentration and 
solubility of drug, type of matrix and other physical properties of the 
starting materials. Some tablet properties such as hardness and 
disintegration are more sensitive than others (dissolution and 
friability) to changes in the processing variables. 
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TABLE XXXV 
Hydrochlorothiazide Fonnulations with Soluble or Insoluble Matrix 
(Granule and Tablet Properties) 
Phase I I I II I 
Fonnulation 12 13 12 13 12 
% W/W Granulating fluid/ 6.7/100 7.7/116 9.3/140 9.9/149 14.0/210 
Mixing time (sec.) 
Linearity - 19.4 17.8 19.5 18.5 
Bulk Density (g/cm3) 
Loose 0.439 0.892 0.456 0.934 0.473 
Tapped o. 711 1.135 0.678 1.160 0.647 
% Compressibility 38.3 21.4 32.7 19.5 26.9 
Compression Force x - 6412 2264 6392 2195 
(Newtons) S.D - 235 88 328 54 
Ejection Force x - 129 109 146 113 
(Newtons) S.D - 4 3 10 3 
~ 
13 
13.8/207 
19.4 
1.069 
1.336 
20.0 
6303 
172 
124 
5 
,--
w 
'-I 
TABLE XXXV ----Continued 
Phase 
Formulation 
Weight (mg) 
Hardness (kg) 
Friability (% loss) 
Disintegration 
(minutes) 
Dissolution 
minutes 15 
30 
45 
x 
S.D 
x 
S.D 
x 
S.D 
x 
S.D 
I 
12 
-
-
-
-
-
-
-
13 
165.0 
2.9 
5.3 
0.6 
0.06 
10. 92 
0.59 
92.75 
1.42 
97.53 
0.46 
98.10 
0.68 
~ 
12 
141.4 
2.4 
3.6 
0.6 
0.18 
6.92 
0.50 
II 
13 
167.0 
3.5 
6.2 
0.6 
0.09 
13.67 
0.52 
Percent drug dissolved 
92.72 90.84 
2.29 2.31 
100.81 97.98 
2.15 1. 31 
101.40 99.44 
1.61 0.79 
12 
141.2 
2.0 
3.2 
0.4 
0.18 
8.42 
0.41 
91.90 
2.13 
101.01 
1.16 
102.00 
0.82 
II I 
13 
165.4 
3.8 
6.3 
0.5 
0.48 
16.92 
0.26 
95.39 
1.45 
99.09 
0.70 
99.28 
0.65 
~ 
( 
( 
Based on this information, phase III was selected as an end point. 
The author then designed two factorial experiments, details of which are 
given below. 
* A factorial design is shown in Figure 51 • This experimental 
design was used to study the effect of type of binder, binder 
concentration and the type of granulation fluid (3 x 2 x 3) on the wet 
granulation process. Tables VIII and IX show the independent variables 
and the factor level in experimental units. Granulating fluid / mixing 
time needed to reach the terminal portion of phase III of the 
experiments is seen in Table XXXVl. These data show that the higher 
level of povidone in the formulation required the lower amount of 
granulation fluid, for phase III wet granulation process. In the case of 
Methocel and Klucel, there is no general conclusion can be drawn, based 
on these data. 
Particle size distributions of granulations from these experiments 
showed (Table XXXVII-XXXIX) that an increase in mean particle size was 
seen with the increase of binder level in the formulation. A General 
Linear Model was used to analyze the data using the SAS package. Binder, 
binder level and granulating fluid exerted statistically significant (P 
0.05) effects on the flow properties of granulations, ejection force, 
hardness, disintegration time and dissolution at fifteen minutes and 
thirty minutes. In addition, that can be drawn all two-way and the 
single three-way interactions were significant. 
* The author gratefully acknowledges help from Dr. W.D. Lawing in design 
of the study and interpretation of results. 
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FIGURE 51 
Experimental design I: Factorial design 
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TABLE XXXVI 
Experimental Design I % W/W Granulating Fluid / Mixing Time (Seconds) 
Povidone Me tho eel Klucel 
3% 6% 3% 6% 3% 6% 
Water 14.1/358 12.5/320 18.5/464 19.7/493 16.7/421 12.5/320 
14.1/358 16.7/421 
3A ethanol 14.5/368 12.2/313 27.1/672 20.1/502 16.0/404 16.4/414 
.+:» 
0 
Isopropanol 14.5/368 12.5/320 18.0/452 23.2/577 17.8/447 20.4/510 
12.5/320 20.4/510 
r--
....... 
~ 
...... 
~ 
TABLE XXXVII 
Experimental Design I 
Percent Particle Size Distribution of Hydrochlorothiazide Granulations 
Granulating Fluid: Water 
Povidone Methocel Klucel 
Size {µm) 3% 6% 3% 6% 3% 6% 
·~ 
---------------------------------------------------------------------------------
0 - 74 17.9 7.9 17.8 9. 2 15.8 8.2 
74 - 105 3.5 1. 7 3. 1 1. 8 2. 6 3. 1 
105 - 149 6.0 2.6 3.7 2. 5 3.9 4.9 
149 - 250 14.6 8.3 8. 1 7.4 10.5 12.8 
250 - 420 22.1 2 5. 1 18.0 21. 7 23.4 25.7 
420 - 840 35.4 5 3. 7 48.4 57.1 43.5 44.9 
840 - 1000 0.5 0.8 0.9 0.2 0.3 0.4 
,,..--._ 
I-' 
~ 
'.I') 
~ 
TABLE XXXVIII 
Experimental Design I 
Percent Particle Size Distribution of Hydrochlorothiazide Granulations 
Granulation Fluid: 3A Denatured alcohol 
Povidone Methocel Klucel 
Size (µm) 3% 6% 3% 6% 3% 6% 
-----------------------------------------------------------------------------
0 - 74 16.9 13.2 58.9 56.1 14.2 10.6 
74 - 105 2.2 2.7 6.0 15.0 2.8 2. 7 
105 - 149 3. 3 3.3 4.6 10.4 3.4 3.3 
149 - 250 9. 3 7. 2 7.8 8.3 9.2 8. 1 
250 - 420 25.1 19.9 13.1 7.0 22.2 20.9 
420 - 840 42.7 51. 7 9.4 3.3 47.9 53.7 
840 - 1000 0.4 2.0 0. 1 0.0 0.3 0.8 
~ 
r--... ,,----...,_ ~ 
TABLE XXXIX 
Experimental Design I 
Percent Particle Size Distribution of Hydrochlorothiazide Granulations 
Granulation fluid: Isopropanol 
Povidone Methocel Klucel 
Size (µm) 3% 6% 3% 6% 3% 6% 
---------------------------------------------------------------------------------
a - 74 12. 7 9. 5 66.5 66.5 2a.1 18.8 
....... 
~ 
w 74 - 1a5 2.9 1. 9 15. 1 12.9 2.8 4.1 
1a5 - 149 4.8 2.4 7. 3 9.4 3.2 4.5 
149 - 25a 15.6 7.6 8.8 8. 1 7.3 9.5 
25a - 42a 3a.2 2 3. 5 1. 9 2. 6 18.2 20.8 
42a - 84a 33.6 54.4 a.4 0.5 47.9 40.3 
840 - 1000 a.2 0.7 a.a o.o a.4 1. 9 
( 
( 
The results are shown in tables XL thru L. Formulations containing 
methocel produced unsatisfactory granules when granulated with 3A 
ethanol and isopropanol. Binders at six percent level in the 
formulations produced significantly better flowable and compressible 
granulations compared to three percent level (Fig. 52). Percentage 
compressibility data calculated from bulk density data supported powder 
flow measurements obtained using Recording Powder Flowmeter. Tablets 
were compressed by setting tablet weight at 135mg and compression force 
at 6KN. The higher level of binder in formulations was reflected in 
lower ejection force in the tablet operation. Compression and ejection 
profiles are seen in Figures 53 thru 70. Granulations prepared with 
povidone or Klucel as binder, 3A ethanol or isopropanol as granulating 
fluid produced harder tablets compared to the granulations made with 
water as granulating fluid. Ejection profiles showed that the higher the 
binder level in formulation at higher compressional forces, the lower 
ejection force was needed to eject the tablets out of the die. At lower 
compressional forces no significant difference in ejection force was 
seen. This property can be attributed to the lower elastic recovery of 
tablets compressed with higher compressional forces. Although, these 
formulations contained two percent disintegrant (Ac-Di-Sol), tablet 
disintegration (Table XLVll) seem to be slower with the tablets 
containing higher level binders. Tablet dissolution data are recorded in 
tables XLVlll thru L. All the factors exerted statistically significant 
effects on dissolution at fifteen and thirty minutes, but these effects 
are probably not practically important in production. The dissolution 
144 
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FIGU RE 52 
Experi mental design I: Granulation flo w orofile 
300 
6% Povidone 
250 
3 ;~ Povidone 
-o 200 
s:: 
0 
u 6 Of l< lucel QJ /0 
Ill 
......_ 
Ill ~ E 
"' ( $.... 150 3% Methoce l Q") 3% Klucel 
w 
I-
< 
CY 
~..; 100 0 
__J 
l.J.... 
6 Of 
,o Methocel 
50 
I SE M 
GRANU LAT I NG FL UI D 
( 145 
(/) 
(/) 
w 
FIGURE 53 
Experimental design I: Colrlpression profile: 3 ;£ Povidone 
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Experimental design I: Compre~sion profile: 6% Povidone 
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FIGURE 55 
Experimental design I: Compression profile: 6% Methocel 
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FIGURE 56 
Experimental design l: Co mpression profile: 3% Klucel 
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FIGURE 57 
Experimental design 1: Compression profile: 6% Klucel 
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Ex per i.rnental de s i gn 1: Compre ss i.on pr of il e : 
Wate r w/ 3% binde r s 
0 Po vidone 
Q Methocel 
e Kluce l 
10.0 
CJ) /1 ~ ( VJ 7.5 VJ 
LLJ ,/~ :z:: Cl O'.'. 
<::( ! // ::c 
/ 5 .0 / / 0 y/ 
2.5 [,~ 
/ 
COMPRESSI ON FOR CE ( KN ) 
151 
FI GU RE 59 
Experi ment a l design I : Compres s ion p r ofile: 
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FIG URE 60 
Experi·ment a l design I: Co mpres s ion profile: 
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Experimental design I: Compression profile: 
3A et hanol w/ 6% bin de rs 
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FIGU RE 62 
Experi mental design I: Co mpression profile: 
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Experimental design ~: Cor:ipression profile: 
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FIGURE 64 
Experimental design J: Ejection profile: 
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FIGURE 65 
Experi ment al design I: Eject ion profile: 
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Experi men t al de s i gn 1: Ejec t ion profile : 
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Exp e ri mental design 1: Ej ection prof il e: 
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Experi mental design I: Ejection profile: 
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Experimental design J: Ejection profile: 
Isopropanol / rovidone 
0 3 ~( 
2 4 6 8 l 0 l 2 
COMPRESSION FORCE lKN} 
162 
( 
( 
~200 
0 
+-' 
3 
a; 
w 
u 
er::. 
0 
LL 
0 
......... 
1-
u 
~l 00 
w 
0 
FIGURE 70 
Experimental design I: Ejection profile: 
Isopropanol / Klucel 
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TABLE XL 
~ 
Experimental Design I : Granulations Flow Rate (g / sec) --X (S.D) 
Povidone Methocel Klucel 
3% 6% 3% 6% 3% 6% 
------------------------------------------------------------------------------------------------
Water 179.9 (4.6) 271.7 {0.1) 161.9 {5.4) 225.2 {0.1) 225.6 {7.7) 254.9 {6.6) 
205.6 (6.8) 219.5 (4.9) 
3A ethanol 203.8 {8. 7) 217.5 {4.7) B* 79.2 {28.1) 226.4 {5.8) 245.7 {3.6) 
....... 
O"I 
..j::>. Isopropanol 209.5 (2.6) 266.8 (10.9) B* B* 141.5 (2.0) 181.0 (3.3) 
249.6 ( 8.7) 185.2 {6.1) 
B* = Blocked. 
,,-----.. 
....... 
"' <.n 
Experimental Design l 
Water 
3A ethanol 
Isopropanol 
3% 
0.910 
1. 094 
0.899 
1. 099 
0.886 
1. 05 7 
0.833 
0.979 
Povidone 
6% 
0.897 
1. 096 
0.937 
1. 108 
0.896 
1.038 
0.898 
1. 040 
,,----..._ 
TABLE XLI . 
Granulations Bulk Density: Loose (g/cm 3 ) 
Tapped 
Me tho eel 
3% 
0 . 878 
1. 066 
0.879 
1. 326 
0.822 
1. 17 3 
6% 
0.764 
0.928 
0.769 
1. 066 
0.807 
1. 146 
3% 
0.916 
1. 082 
0.910 
1. 085 
0.857 
1. 040 
0.923 
1.126 
Klucel 
,.---. 
6% 
0.828 
0.991 
0.819 
0.962 
0.896 
1. 068 
0.902 
1. 071 
...... 
O'I 
O'I 
,,.----.. ~ 
TABLE XLII 
Experimental Design I: Percentage Compressibility of Granulations 
Water 
3A ethanol 
Isopropanol 
3% 
16.8 
18.2 
16.2 
14.9 
Povidone 
6% 
18.2 
15.4 
13.7 
13. 7 
Methocel Klucel 
3% 6% 3% 
17.6 1 7. 7 15. 3 
16.1 
33.7 27.9 18.3 
29.9 29.6 17. 6 
,.---..._ 
6% 
16.4 
14.9 
16. 1 
15.8 
r-' 
...... 
°' -.....J 
Water 
3A ethanol 
Isopropanol 
,----.... 
TABLE XLI·II 
Experimental Design r : Compression Force (Newtons) X (S.D) 
Povidone 
3% 
6034 
( 171) 
6083 
{160) 
6052 
( 5 1 1 ) 
6% 
6059 
( 2 1 9 ) 
6029 
{279) 
5950 
(423) 
Methocel 
3% 
6012 
(249) 
6% 
6092 
( 2 35) 
6033 
{259) 
Klucel 
3% 
6087 
( 213) 
5950 
{332) 
6006 
{249) 
·~ 
6% 
5963 
{185) 
6065 
(319) 
6035 
{579) 
..-- ~ ~ 
TABLE XLI.V- . 
Experimental Design I : Ejection Force (Newtons) X (S.D) 
Povidone Methocel Klucel 
3% 6% 3% 6% 3% 6% 
Water 185 162 184 146 164 108 
( 6) ( 4 ) ( 8 ) ( 5) ( 5) ( 5 ) 
I-' 
°' 3A ethanol 206 183 - 153 149 104 co ( 4 ) ( 6) - ( 7) ( 9) ( 5 ) 
Isopropanol 192 158 - - 149 104 
( 17) ( 6 ) - - ( 6 ) ( 3 ) 
* Compression Force 6000 Newtons 
...... 
(j\ 
l.D 
Water 
3A ethanol 
Isopropanol 
·-----
TABLE XLV . 
Experimental Design I : Tablet Hardness (kg) X (S.D) 
Povidone Methocel 
3% 6% 3% 6% 3% 
5.50 8.50 6.50 7. 00 5.00 
(0.38) (0.55) (0.72) (1.13) (0.33) 
6.00 10.03 - 5.37 5.32 
( 0. 43) (1.02) - (0.45) (0.31) 
7.01 9. 12 - - 5.68 
( 0 . 5 5 ) (0.31) - - (0.56) 
.----... 
Klucel 
6% 
7.70 
(0.43) 
10.50 
( 0 . 9 5 ) 
10.40 
( 0 . 8 1 ) 
,,---. 
..... 
-.....J 
0 
Water 
3A ethanol 
Isopropanol 
,,,.---.., ~ 
TABLE XLVI 
Experimental Design I : Tablet Friability (%Loss) 
Povidone Methocel Klucel 
3% 6% 3% 6% 3% 6% 
0.08 0.10 0.08 0.10 0. 13 0.10 
0.08 0.07 0.22 0.00 0.05 
0.05 0.05 0.08 0.05 
,,...--.._ 
I-' 
'-! 
I-' 
Water 
3A ethanol 
Isopropanol 
Experimental Design I 
Povidone 
3% 6% 
2.38 16.92 
(0.14) (0.49) 
1. 00 13.42 
(0.00) (1.02) 
3.33 19.92 
(0.44) (1.74) 
~ .----... 
TABLE XLVII 
Tablet Disintegration (Minutes) X (S.D) 
Methocel Klucel 
3% 6% 3% 6% 
6.08 17.08 1. 00 9.42 
(0.13) (0.67) (0.00) (0.43) 
- 0.53 0.88 25.50 
- (0.03) (0.20) (1.41) 
- - 3.02 18.63 
- - (0.28) (1.51) 
,,..--.. ~ ..........._ 
TABLE XLVIII 
Experimental Design I 
Tablet Dissolution - Percent Drug Dissolved at 15 Minutes. X (S.D) 
Povidone Methocel Klucel 
3% 6% 3% 6% 3% 6% 
---------------------------------------------------------------------------------
Water 96.97 83.49 83.68 78.31 96.51 95.75 
(0.64) (3.15) (0.22) (2.57) (0.77) (1.77) 
...... 
" 
3A ethanol 96.66 93.67 - 93.47 97.99 94.43 N (0.89) (1.75) (1.24) (1.37) (1.67) 
Isopropanol 95.59 80.62 - - 98.03 97.52 
(1.49) (3.91) (2.00) ( 0 . 9 0 ) 
....... 
-....J 
w 
,,..---._ 
,,-----.. 
TABLE XLIX 
Experimental Design I 
Tablet Dissolution - Percent Drug Dissolved at 30 Minutes. X (S.D) 
Povidone Methocel Klucel 
3% 6% 3% 6% 3% 
Water 98.60 97.50 9 3. 11 92.00 99.50 
(0.56) (1.02) (0.33) {1.04) (0.45) 
3A ethanol 98.27 96.62 - 95.40 99.57 
(1.01) (0.53) (0.95) (0.97) 
Isopropanol 99.23 95.61 - - 99.36 
(0.53) (0.89) ( 0 . 7 1 ) 
..----., 
6% 
99.78 
( 0 . 8 1 ) 
97.14 
{O. 76) 
99.91 
{0.47) 
,----...._ 
~ 
,,.--. 
TABLE L 
Experimental Design I 
Tablet Dissolution - Percent Drug Dissolved at 45 Minutes. X (S.D) 
Povidone Methocel Klucel 
3% 6% 3% 6% 3% 6% 
Water 99.87 98.33 95.97 96.40 99.85 100.90 
(0.15) (0.89) (0.84) (0.81) (0.24) (1.21) 
...... 
99.10 97.23 - 96.74 99.90 99.90 
( 0 . 7 4 ) (0.49) (0.40) (0.20) (0.17) 
~ 3A ethanol 
Isopropanol 99.40 97.28 - - 99.40 99.92 
(0.56) (0.87) (0.72) (0.17) 
( 
( 
specification (USP) for these tablets requires that eighty percent of 
label drug has to be dissolved within 30 minutes. 
A factorial design to study the effect of type of disintegrant, 
concentration of disintegrant and the location of disintegrant in the 
granules on the wet granulation process is shown in Tables XI thru XIII. 
Granulations flow rate are recorded in Table LI. Intragranular 
disintegrants (up to 2.0%) in the formulation improved flow properties 
of granulations. However, in the case of four percent Ac-Di-Sol in the 
granulation, the flow of granulation was adversely affected. Explotab 
and crospovidone showed no effect at this level. 
Bulk density of granules decreased with the increased 
concentration of disintegrant in the formulation (Table LII). These 
disintegrants did not have any effect on tablet weight variation, 
ejection force, hardness and friability of the tablet (Tables LIV-LIX). 
Thickness of tablets containing disintegrants was increased slightly. 
All the factors exerted statistically significant effects (P <0.05) on 
disintegration time, dissolution at fifteen minutes and at thirty 
minutes. A General Linear Model was used to analyze the data. Tablet 
disintegration and dissolution results are recorded in Tables LX thru 
LXII. Intergranular disintegrant on dissolution rate is significantly 
better than intragranular disintegrant, irrespective of the 
disintegrants (Fig 1 s. 71-76). Intragranular crospovidone and Starch 1500 
in this system seem to be missing part of their disintegration action 
due to the wet granulation process (Fig 1 s. 72-76). These results 
indicate that 50% intra- plus 50% intergranular disintegrant on 
dissolution of tablet at fifteen minutes is better than 100% 
175 
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Experimental Design II 
Total % Ac-Di-Sol 
Disintegrant 
0.00 227.46 
(9.19) 
0.25 253.82 
( 3 . 7 2 ) 
..,.... 0.50 254.11 
" (7.58) 0) 
1. 00 204.12 
(7.34) 
2.00 215.90 
(2.66) 
4.00 182.76 
(0.04) 
8.00 -
16.0 -
,..----..,. 
TABLE LI 
' Granulation Flow Rate (Grams I Second) X (S.D) 
Explotab 
204.56 
( 14. 83) 
247.80 
(6.25) 
260.69 
(3.77) 
267.98 
(4.04) 
265.98 
( 1 0 . 9 2 ) 
228.94 
(3.05) 
-
-
Cros-
povi done 
215.65 
(10.53) 
265.60 
(7.80) 
256.38 
(6.53) 
246.02 
(3.54) 
252.17 
(3.67) 
212.38 
( 3. 99) 
-
-
Starch 1500 
246.81 
(3.51) 
225.59 
( 5 . 9 1 ) 
252.38 
(7.22) 
236.23 
(6.50) 
205.57 
(4.31) 
-----._ 
( 
( 
Experimental Design ii 
Total % Ac-Di-Sol 
Disintegrant 
TABLE LIJ 
Granulations Bulk Density: Loose (g I cm3) 
Tapped 
Explotab Cros- Starch 1500 
povidone 
------------------------------------------------------------------------
0.00 1.122 1.123 1.129 
1.350 1. 361 1.386 
0.25 0.945 0.988 1.011 
1.098 1.155 1.162 
0.50 0.913 1.040 1.060 
1.070 1.201 1. 216 
1.00 0.888 0.980 0.988 0.945 
1.060 1.149 1.174 1.089 
2.00 0.857 0.946 0.908 0.916 
1.011 1.077 1.061 1.062 
4.00 0.754 0.832 o. 771 0.856 
0.912 0.968 0.892 0.980 
8.00 0.804 
0.927 
16.0 0.741 
0.867 
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Experimental Design II 
Total % Ac-Di-Sol 
Disintegrant 
0.00 17.6 
0.25 13.9 
0.50 14.7 
1.00 16.2 
2.00 15.2 
4.00 17.3 
8.00 
16.0 
( 
TABLE LI II 
Percent Compressibility of Granulations 
Explotab 
14.5 
13.4 
14.7 
12.2 
14.0 
178 
Cros-
povi done 
13.0 
12.8 
15.8 
14.4 
13.6 
Starch 1500 
13.2 
13.7 
12.7 
13.3 
14.5 
~ ~ 
TABLE LIV 
Experimental Design II Compression Force (Newtons) ~ (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-----------------------------------------------------------------------------
Control 0 3532 (138) 
0.25 0 3555 ( 93) 3550 ( 90) 3711 (163) 
I-" 
-...J 0.25 100 3553 (214) 3344 (149) 3454 (128) I.Cl 
0.50 0 3590 (121) 3561 (124) 3540 (265) 3589 (158) 
0.50 50 3365 (121) 3567 (161) 3373 (157) 
0.50 100 3437 (145) 3411 (131) 3550 ( 77) 
1. 00 0 3314 ( 92) 3513 ( 90) 3563 ( 71) 3586 (144) 
1. 00 50 3564 (361) 3612 (135) 3666 ( 88) 3322 (154) 
1. 00 100 3559 (206) 3528 (191) 3541 ( 88) 3577 (178) 
~ 
----.., 
TABLE LIV ---Continued 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-----------------------------------------------------------------------------
2.00 0 3495 (123) - - 3556 (130) 
2.00 50 3571 (119) - - 3407 (145) 
....... 2.00 100 3371 ( 69) - - 3518 (121) 
00 
0 
4.00 0 3400 (153) - - 3699 (153) 
4.00 50 3344 (117) - - 3482 (150) 
4.00 100 3559 (104) - - 3692 (167} 
~ 
,----.. 
,....---..._ 
TABLE LV 
Experimental Design II Ejection Force (Newtons) X (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-----------------------------------------------------------------------------
Control 0 118 (7) 
0.25 0 126 (5) 129 (6) 139 (5) 
0.25 100 132 (9) 127 (8) 128 (7) 
...... 
co 
...... 0.50 0 121 (7) 124 (5) 124 (12) 131 (6) 
0.50 50 133 (9) 121 (8) 123 (4) 
0.50 100 126 (8) 125 (5) 123 (4) 
1. 00 0 112 (8) 120 (5) 125 (5) 121 (7) 
1. 00 50 131 (14) 116 (6) 132 (6) 123 (6) 
1. 00 100 127 (7) 125 (4) 126 (3) 124 (10) 
,,..--. 
....... 
00 
N 
TABLE LV ----Continued. 
Total % % Intra Ac-Di-Sol 
Disintegrant 
,,---., 
Explotab Cros-
pov i done 
Starch 1500 
-----------------------------------------------------------------------------
2.00 0 108 (5) - - 113 (6) 
2.00 50 127 (7) - - 112 (5) 
2.00 100 110 (4) - - 120 (6) 
4.00 0 106 (5) - - 110 (7) 
4.00 50 110 (5) - - 114 (4) 
4.00 100 117 (4) - - 115 (6) 
.--..... 
r---. ~ 
TABLE LVI 
Experimental Design II : Tablet Weight (mg) X (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-------------------------------------------------------------------------------
Control 0 201.2 (2.64) 
0.25 0 200.7 (1.86) 202.2 (1.83) 202.5 (1.38) 
0.25 100 198.2 (3.37) 196.2 (1.83) 198.8 (1.83) 
....... 
0.50 0 201.2 (2.14) 197.5 (1.97) 201.5 (1.64) 200.7 (1.75) 
co 
w 
0.50 50 202.5 (1.22) 196.8 (2.04) 200.5 (2.66) 
0.50 100 201.3 (2.66) 199.7 (3.01) 200.2 (1.60) 
1. 00 0 200.2 (1.17) 202.3 (2.80) 198.2 (0.75) 200.2 (0.75) 
1. 00 50 200.2 (2.08) 197.0 (1.67) 204.2 (0.84) 201.3 (1.86) 
1. 00 100 203.5 (2.59) 199.6 (0.92) 199.0 (0.84) 201.3 (2.07) 
........ 
co 
.j:::. 
,,,----
TABLE LVI ---- Continued 
Total % % Intra Ac-Di-Sol 
Disintegrant 
Explotab Cros-
pov i done 
~ 
Starch 1500 
-------------------------------------------------------------------------------
2.00 0 198.2 (1.72) - - 200.3 (1.10) 
2.00 50 200.3 (2.50) - - 201. 2 ( 1. 2 3) 
2.00 100 197.8 (1.83) - - 201.5 (1.38) 
4.00 0 196.7 (1.69) - - 203.5 (0.84) 
4.00 50 195.8 (1.72) - - 202.5 (1.64) 
4.00 100 201.5 (1.05) - - 205.0 (0.75) 
,.---.... 
~ 
TABLE LVII 
Experimental Design II : Tablet Hardness (kg) X (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-------------------------------------------------------------------------------
Control 0 3.88 (0.42) 
0.25 0 4.33 (0.51) 4.93 (0.40) 4.77 (0.55) 
0.25 100 3.65 (0.21) 4.10 (0.58) 4.13 (0.51) 
....... 
o:> 0.50 0 6.12 (0.69) 3.70 (0.28) 4.60 (0.36) 4.23 (0.27) (}1 
0.50 50 6.60 (0.93) 3.12 (0.13) 3.67 (0.31) 
0.50 100 5.48 (0.37) 4.55 (0.53) 3.62 (0.24) 
1. 00 0 4.38 (0.38) 4.03 (0.37) 3.63 (0.15) 4.18 (1.06) 
1. 00 50 5.00 (0.52) 3.57 (0.12) 3.83 (0.21) 3.98 (0.21) 
1. 00 100 5.53 (0.49) 4.65 (0.48) 4.13 (0.88) 4.63 (0.58) 
,---....,,_ 
,.-----.,, 
-
TABLE LVII ---Continued 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-------------------------------------------------------------------------------
2.00 0 4.60 (0.23) - - 3.72 (0.28) 
2.00 50 5.90 (0.51) - - 5.03 (0.67) 
2.00 100 6.20 (0.76) - - 4.35 {0.52) 
I-' 4.00 0 4.22 (0.25) co - - 3.92 (0.46) 
O'I 
4.00 50 5.42 (0.25) - - 5.57 (0.35) 
4.00 100 7.45 (0.30) - - 6.21 (0.58) 
( TABLE LVI II 
Experimental Design II : Tablet Thickness (inches) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
------------------------------------------------------------------------
Control 0 0.149 
0.25 0 0.152 0.151 0.152 
0.25 100 0.152 0.151 0.151 
0.50 0 0.150 0 .149 0.152 0.152 
0.50 50 0.153 0.149 0.152 
0.50 100 0.153 0.150 0.152 
1.00 0 0.152 0.152 0.153 0.152 
1.00 50 0.152 0.150 0.153 0.152 
1.00 100 0.153 0.150 0.152 0.153 
2.00 0 0.152 0.153 
2.00 50 0.153 0.153 
2.00 100 0.153 0.153 
4.00 0 0.153 0.158 
4.00 50 0.154 0.157 
4.00 100 0.156 0.158 
187 
( TABLE LIX 
Experimental Design II : Tablet Friability (%Loss) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
------------------------------------------------------------------------
Control 0 0.15 
0.25 0 0.15 0.12 0.10 
0.25 100 0.13 0.15 0.18 
0.50 0 0.08 0.18 0.15 0.12 
0.50 50 0.07 0.21 0.23 
0.50 100 0.15 0.18 0.23 
1.00 0 0.15 0.15 0.15 0.15 
1.00 50 0.15 0.23 0.15 0.10 
( 1.00 100 0.15 0.15 0.26 0.05 
2.00 0 0.18 0.17 
2.00 50 0.15 0.20 
2.00 100 0.13 0.15 
4.00 0 0.33 0.22 
4.00 50 0.10 0.30 
4.00 100 0.10 0.10 
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TABLE LX 
Experimental Design II Tablet Disintegration Time (minutes) X (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-------------------------------------------------------------------------------
Control 0 >3 0. 0 0 
0.25 0 4.38 (0.57) 14.98 (2.34) 9.83 (1.54) 
0.25 100 14.92 (4.20) 20. 9 5 ( 1. 31) >3 0. 0 0 
i-o 
00 0.50 0 4.30 (0.97) 4.01 (0.35) 4.54 (0.75) 23.67 (3.72) ~ 
0.50 50 12.95 (1.46) 8.10 (0.74) 25.83 (0.61) 
0.50 100 13.85 (1.37) 14.76 (0.24) >~30.00 
1. 00 0 2.68 (0.69) 3.58 (0.09) 2.50 (0.22) 7.30 (1.49) 
1. 00 50 9.30 (0.63) 4.75 (0.27) 9.83 (1.36) 22.67 (5.12) 
1. 00 100 9.21 (1.10) 9.25 (1.64) 24.63 (2.54) >30.00 
,---... 
~ 
TABLE LX ----Continued 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-------------------------------------------------------------------------------
2.00 0 2.05 (0.26) - - 7 • 7 1 ( 1 . 5 4 ) 
2.00 50 5.93 (0.32) - - 21.75 (4.35) 
2.00 100 6.15 (0.44) - - >3 0. 00 
...... 
c.o 
0 4.00 0 1.91 (0.46) - - 3.63 (0.35) 
4.00 50 4.30 (0.10) - - 20.75 (3.31) 
4.00 100 5.08 (0.07) - - 20.54 (4.45) 
~ 
TABLE LXI 
Experimental Design II 
Tablet Dissolution - Percent Drug Dissolved at 15 minutes. ' X (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-----------------------------------------------------------------------------
Control 0 21.83 (3.24) 
0.25 0 92.43 (1.04) 78.12 (7.05) 95.22 (0.82) 
I-' 
l.O 0.25 100 76.00 (10.44) 53.65 (11.92) 30.91 (3.36) I-' 
0.50 0 92.05 (3.53) 96.60 (1.73) 96.79 (1.26) 90.61 (2.76) 
0.50 50 60.03 (4.98) 85.92 (1.76) 84.87 (3.68) 
0.50 100 89.14 (3.25) 49.97 (10.93) 55.38 (6.20) 
1. 00 0 95.29 (1.52) - - 96.41 (1.16) 
1. 00 50 90.68 (0.70) - - 89.90 (2.76) 
1. 00 100 90.47 (1.92) 72.52 (1.96) 91.76 (1.95) 27.41 (8.86) 
2.00 100 - - - 41.72 (5.81) 
4.00 100 - - - 70.06 (3.71) 
-
------. 
-----.. 
TABLE LXII 
Experimental Design II 
Tablet Dissolution - Percent Drug Dissolved at 30 Minutes. X (S.D) 
Total % % Intra Ac-Di-Sol Explotab Cros- Starch 1500 
Disintegrant povidone 
-------------------------------------------------------------------------------
Control 0 36.18 {5.27) 
0.25 0 99.58 (0.87) 97.84 (0.79) 99.18 (1.12) 
I-' 0.25 100 98.07 (1.62) 93.96 {3.44) 67.91 {7.60) 
\D 
N 
0.50 0 97.00 (1.58) 99.16 (1.22) 99.68 (0.68) 98.94 ( 1.32) 
0.50 50 92.50 {1.74) 92.94 (0.81) 98.72 {1.30) 
0.50 100 96.07 (1.12) 91.52 (3.33) 96.30 (0.97) 
1. 00 0 97.14 (1.14) - - 98.96 ( 0.74) 
1. 00 50 95.19 (0.45) - - 98.62 ( 1.95) 
1. 00 100 94.10 (1.23) 98.08 (0.62) 99.20 (0.80) 54.56 {16.00) 
2.00 100 - - - 94.50 ( 2.65) 
4.00 100 - - - 100.00 ( 0.43) 
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Experi mental de s ign II : 
Dissolution profil e of 0 .25 % dis i nte gr ant s 
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FIGURE 72 
Experimental design II: 
DissoJution profile of 0.5 % intragranular disintegrants 
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FIGURE 73 
Experimental design II: 
Dissolution profile of l . 0% intragranular disintegrants 
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( Experimental design II: 
Dissolution profile of formulations w/ Explotab 
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( Experimental design II: 
Dissolution profile of formulations with crospovidone 
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( FIGURE 76 
Experimental deisgn II: 
Dissolution profile of formulations with Starch 1500 
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intragranular disintegrant but worse than 100% intergranular 
disintegrant. 
Figure 77 shows the effect of different grades of lactose (Table 
XIV) on the torque profile of the wet granulation process. The lactose 
hydrous (finer grade) produced all five distinct phases reported earlier 
(with 30 percent w/w water). The lactose anhydrous (coarse grade) showed 
condensation of phase I, II and III. This material was not overwet with 
30 percent granulation fluid. Furher, phase V was not apparent in the 
torque profile. This instrumentation is sensitive to changes in the 
particle size of raw materials. This behaviour with coarse size lactose 
can be related to the total surface area of the powder; with particle 
size increase, the surface area decreases, so the quantity of liquid 
needed to create bonds between particles is also less. The quantity of 
liquid required for granulation is a straight line function of the 
inverse of the particle size (97). 
Figure 78 shows the effect of different levels of sucrose (soluble 
material) in the formulation on the torque profiles. The results show 
that the higher the level of soluble material in the formulation, the 
lower the amount of granulating fluid required for optimum granulation 
process. The granulation fluid required for agglomeration seems to be a 
function of log concentration of the soluble material in the 
formulation. Obviously, we need much more data and this should be a 
subject of future research. Hardesty reported (33,34), that the moisture 
requirement for agglomeration decreases linearly with increasing 
proportion of salt in the granulation fluid. 
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FIGURE 77 
Formulations T4 and 15: 
Effect of different grades of lactose on the torque profile 
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Formulations T6 - 19: 
Effect of different levels of Sucrose on the torque profile 
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Figure 79 shows the effect of different levels of Avicel PH 101 in 
the lactose formulation on the torque profiles. These torque profiles 
indicate that the increase in Avicel PH 101 in the formulation, results 
in an increase in the volume of granulating fluid needed for optimum 
granulation. This phenomenon may be due to the rapid diffusion of 
granulating fluid into the inner pores so that the amount of liquid 
available on the surface of the powder for agglomeration decreases. 
Different levels of microcrystalline cellulose in highly soluble matrix 
formulations are of interest for future work. 
Figure 80 shows the effect of rate of mixing of the lactose 
formulation on the torque profiles. These curves indicate that the 
increase in rate of mixing caused the decrease in the amount of 
granulating fluid required for optimum granulation. A probable 
explanation is that the higher paddle speed causes faster densification 
of granules, squeezes the intragranular liquid out, and that results in 
excess surface moisture. The excess of free surface liquid provided 
rapidly results in agglomeration of nuclei into large agglomerates and 
the process goes into phase IV faster than the process which has slow 
mixing. 
The granule size needed in the pharmaceutical industry is much 
smaller than in the fertilizer industry. Important contributions were 
made in the field of granule growth mechanism in the fertilizer industry 
by Newitt and Conway Jones, Kapur and Fuerstenau, Capes and Danckwerts, 
Rumpf, and Sastry. All the researchers studied granule growth mechanism 
in a wet pelletising dish or rotary drum. Three different mechanisms of 
granule growth were agreed to by most workers (i.e., coalescence, 
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FIGURE 79 
Formulations 20 - 22: 
Effect of different levels of Avicel PHlOl on the torque profile . 
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FIGURE 80 
Formulation 23: 
Effect of different rates of mixinq on the torque profile 
TIME (secondsl 0 
Top Medium speed (258 rpm) 
Bottom: Slow speed (145 rpm) 
layering, and nucleation by coalescence and granule growth by layering). 
In the present study, scanning electron micrographs of the granulations 
suggest that the granule growth is due to a coalescence mechanism. These 
photographs also indicate that nucleation of granulation is in progress 
from phase I of the process. The actual granule growth was observed 
visually in phase III of the process. At the end of phase III, all the 
granules were wet and shiny. This observation suggests that the 
capillary state (23) is reached (all the pore spaces in the granules are 
completely filled). Due to the shear and compaction forces in the 
planetary mixer, these granules grow uncontrollably and form a pasty 
mass in phase IV of the process. If we stop adding the granulating fluid 
at the end of phase III and roll the granulations in a rolling drum we 
may cause further granule growth without forming a pasty mass. In the 
pharmaceutical field, we are not interested in agglomerates of a size 
greater than 2 mm. The author of this thesis strongly feels that the 
moisture available on the surface of the solid material is the only 
liquid available for agglomeration. This can be achieved by adding 
granulation fluid at a slow rate or atomizing the granulation fluid and 
mixing the solid material for uniform dispersion of liquid. There may be 
a relationship between the liquid addition rate and time of mixing to 
achieve uniform wetting of the solid surface. 
The use of torque measuring devices with the large scale equipment 
is possible without radical modification of the equipment. There are 
many different torque measuring instruments available commercially. It 
is a matter of finding a suitable location on the equipment at which to 
install appropriate instruments. If the equipment is operated by a 
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syncronous motor, the power consumption of the motor is a direct 
function of torque applied on the mixing paddle. Leuenberger (39) has 
shown that the power consumption method allows an effective monitoring 
of the granulation process scaleup. He demonstrated linearity of the 
measurements (granulation fluid needed for different phases) in charges 
ranged from 3.75 Kg up to 60 Kg using different types of equipment. The 
ratio of batch size to rate of addition was kept constant. This author 
investigated only one formulation. Although one can keep the ratio of 
batch size to granulating fluid addition constant, there are many other 
variables that can affect the process. 
Process validation is a systematic approach aimed at identifying, 
measuring, evaluating, documenting and reevaluating a series of critical 
steps in the manufacturing process that require control if a 
reproducible final product is to be obtained. The wet granulation 
process is one of the critical steps in the tableting manufacture. This 
study supports the simple theory that the quality of the tablets 
manufactured is often very largely dependent upon the quality of the 
granulations used. The amount of granulating fluid, mixing time, drying 
time, and sizing of the dried granules are the critical variables 
involved in the granulation process. The instrumentation described in 
this thesis is a valuable tool in quantifying the amount of granulating 
fluid needed for optimum granulation irrespective of the type of matrix, 
drug, drug concentration, particle size, rate of addition of granulating 
fluid, type of granulating fluid and rate of mixing. 
206 
( In recent years (post 1982), other techniques for monitoring the 
granulation process have been investigated. Measurement of power 
consumption of a planetary mixer has been used to study wet massing in 
the granulation process and correlations have been made between the 
power consumption curve and the various phases of the wet massing 
process {39,97 and 98). The torque profile of the formulation 1 showed a 
close similarity with the power consumption curve reported in the 
literature {39) of a very similar formulation. It is very difficult to 
compare the results of the present study with the literature data 
because of insufficient information in the literature such as equipment 
size, mixing rate, granulation fluid addition rate and amplification of 
signals. In general, it seems if all the variables are kept constant, the 
power consumption curve could be comparable to the torque profile. 
Leuenberger {39) suggested the following equation to make a theoreticle 
estimate of the quantity of granulation liquid required in the 
granulation process. 
W =weight fraction of granulating liquid needed for optimum 
agglomeration 
-Y~ 0.213 (mean percent pore space between cubic and 
rhombohedral particle packing) 
E= porosity obtained by tamped density measurements 
p = true density of particles 
s 
p 2 = density of granulating liquid 
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oH= equlibrium moisture uptake of the solid materials when 
exposed to 100% relative humidity 
This equation does not take into account of the solubility of the solid 
material in the granulation fluid, and also the oH term does not take 
into account that the solid which picks up moisture may also be soluble 
in the same moisture. For example this oH term predicts more moisture 
requirement for the formulation containing higher level of povidone. 
Povidone is highly hygroscopic material. The study in this thesis showed 
that as the povidone level in the formulation was increased, the 
granulation fluid required for optimum granulation was decreased. This 
finding is in agreement with the observation made by the present author 
that the higher the soluble material in the formulation, the lower the 
amount of granulating fluid needed for optimum granulation. 
Paris et al. (97 and 98) studied the effect of other variables on 
wet granulation. These authors, however, passed the wet granulation 
through a screen which made their study is of limited value. They 
concluded that some mixers are not convenient to produce a good power 
consumption recording, but for a given type of mixer, rate of mixing or 
batch size do not affect the optimal liquid quantity requirement for wet 
granulation. These authors showed that reduction in the particle size of 
lactose used for granulation caused an increase in the amount of 
granulation fluid needed for optimum granulation. Torque measuring 
equipment used in the present study showed that the mixing speed can 
affect the optimum quantity of liquid needed for wet granulation. The 
present study is in agreement with the later finding of the above 
authors. 
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Alleva et al. (99) have studied the rheological properties of 
granulations using the resistance to movement of instrumented deflection 
beams through a shallow bed of granulation. Static measurements are of 
limited value in quantifying the wet granulation process. This test 
requires stopping the process and sampling the granulation for testing 
the reological properties of the wet mass. 
Fry et al. (100) have been used the moisture analyzer interfaced 
with a computer to study the granulation process. This instrumentation 
seems to be a more valuable tool to check the distribution of moisture 
in the powder bed rather than to quantitate the wet granulation process. 
Holm et al. (101-104) studied the granulation of lactose and 
dicalcium phosphate in a high speed mixer (Fielder). These authors 
subjectively selected ten and fifteen percent of granulation fluid and 
studied the effects of process variables on the granulation process. 
These authors showed the increase in impeller speed causes a decrease in 
the volume of granulating fluid needed for wet granulation. This finding 
agrees with the observation reported in this thesis. They also concluded 
that the dicalcium phosphate granule growth is very sensitive to the 
amount of liquid added, whereas in case of lactose, the granule growth 
is more gradual. The dicalcium phosphate requires liquid saturation of 
about 90% for significant granule growth and lactose needs liquid 
saturation less than 50% for granule growth. The author of this thesis 
has noticed a similar effect with dicalcium phosphate and lactose in a 
planetary mixer. 
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IV. CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
The following are believed to be the major points of this work as 
reported and discussed in the previous section. 
I. The instrumentation described in this study can be assembled using 
commercially availab l e equipment. It is cheap and convenient. The data 
generated by this instrumentation are reproducible. 
2. This instrumentat i on is sensitive to all formulation and processing 
variables. 
3. Formulations containing widely used lactose, dicalcium phosphate or 
mannitol matrices produce torque profiles with five distinct phases. The 
study of these phases of the wet granulation process showed that the 
optimum flowable and compressible granulations can be obtained only from 
phase III of the process irrespective of the drug, drug concentration 
and matrix. 
4. Scanning electron micrographs of granulations suggest that the 
mechanism of granule growth is due to a coalescence mechanism. 
5. Finer starting ma t erials require more granulating fluid for optimum 
granulation compared to the coarser starting materials. 
6. Increase in solub l e material in the formulation causes a decrease in 
the amount of granulating fluid necessary for optimum granulation. 
7. As the concentrat i on of drug or soluble material in the formulation 
is increased, the granulation process becomes more sensitive to process 
variables. 
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8. Binder, binder level and granulating fluid exert statistically 
significant effects on flow rate, tablet hardness, and disolution at 
fifteen and 30 minutes. 
9. Disintegrant, disintegrant level and percent intragranular 
disintegrant exert statistically significant effects on disintegration 
and dissolution at fifteen and 30 minutes. 
10. Low viscosity binders (Methocel LV15) do not produce satisfactory 
granules due to their poor bonding strength. 
11. Some tablet properties are more sensitive (hardness, and 
disintegration) to process variables than others (dissolution and 
friability) in the granulation process. 
12. This instrumentation is a valuable tool for optimization and 
validation of wet granulation process. 
Suggestions for future research 
1. There is a need for an equation which can estimate the amount of 
granulating fluid needed for optimum granulation process. The following 
variables have to be given some attention in developing the equation. 
Particle size (or surface area), shape, porosity, density, solubility in 
the granulating fluid (or rate of dissolution of the material in the 
granulating fluid), moisture sorption, granulation liquid density, 
surface tension, and rate of mixing. 
2. Electronic equipment should be developed to automate the granulation 
process using the torque measurements. 
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3. Granulation fluid requirement may be a function of log concentration 
of the soluble material in the formulation. This observation should be 
explored. 
4. Formulations containing different concentrations of microcrystal line 
cellulose with highly soluble solids should be investigated. 
Microcrystalline cellulose may control the moisture available on the 
surface of the solids in the granulation process, and the granule growth 
may be uniform. 
There is thus an immense amount of further research required 
before our knowledge of the granulation process can even be described as 
adequate. The field does not lack challenge, interest or opportunity. 
The big question, however, remains as always: is there ever likely to be 
sufficient motivation and skill for the very demanding experimental and 
theoretical work required ? 
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APPENDIX 1 
Program to calculate tablet dissolution: 
The following Basic program for Apple PC calculates tablet 
dissolution using: volume of dissolution medium, individual tablet 
weight, sampling volume, dilution factor, absorbance (reference) values 
as a function of concentration, and the absorbance (test) values as a 
function of time. The output displays the values of slope, intercept, 
coefficient of determination of Beer's plot, mean percent drug 
dissolved, and amount of drug dissolved in dissolution medium as a 
function of time. In addition, it also calculates mean T50 , T75 , T90 and 
standard deviation. 
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10 REM ******** TABLET DISSOLUTION ******* 
20 PRINT " TABLET DISSOLUTION PROGRAM. WRITTEN BY S.R. GHANTA " 
30 PRINT 
40 PRINT 
50 PRINT " IF MISSING A SAMPLE ENTER INVERSE TIME AND 0 FOR ABSORBANCE " 
60 PRINT 
70 PRINT 
80 INPUT " PRODUCT NAME "; N$ 
90 PRINT 
100 INPUT II LOT # II ;M$ 
110 PRINT " ENTER TOTAL VOLUME IN ML OF DISSOLUTION MEDIA 11 ; A 
120 PRINT 
130 INPUT " ENTER AMOUNT IN ML OF SAMPLE WITHDRAWN 11 ;C 
140 PRINT 
150 INPUT II DILUTION FACTOR 11 ; OF 
160 PRINT 
165 INPUT " ENTER PERCENT ACTIVE IN THE TABLET 11 ; PA 
170 FOR I = 1 TO D 
180 F (I) = 0 : E (I) = 0 E = 0 
190 NEXT I 
200 INPUT II ENTER TABLET WEIGHT 11 ; w 
205 L = W * PA 
210 PRINT 
220 INPUT 11 ENTER # OF SAMPLES ";D 
230 PRINT 
240 0$ = II MG/ML II 
221 
( 
250 PRINT 
260 PRINT 11 ENTER SAMPLE ABSORBANCE, COMMA, AND TIME " 
270 FOR I = 1 TO D 
280 INPUT A (I), B (I) 
290 NEXT I 
300 IF R = 1 THEN 320 
310 GOSUB 730 
320 0$ = " MG/900 ML 11 
330 PRINT 
340 PRINT II TIME "' 0$ ' " % LABEL" 
350 PRINT 
360 F (1) = ((A (1) - B2) I Bl) *A* OF 
370 Q (1) = ( INT ((F (1) IL ) * 10000) I 10000) * 100 
380 IF A (1) = 0 THEN V (1) = V (1) + 1 : Q (1) = 0 : F (1) = 0 
390 PRINT B (1), INT (F (1) * 1000) I 1000, Q (1) 
400 IF D = 1 THEN 500 
410 REM ***** ERROR ROUTINE ***** 
420 FOR I = 2 TO D 
430 E (I) = F (I - 1) I A * C 
440 E = E + E (I) 
450 F (I) = (((A (I) - B2) /Bl) *A* OF) + E 
460 Q (I) = ( INT ((F (I) I L) * 10000) I 10000) * 100 
4 7 0 I F A ( I ) = 0 TH EN V ( I ) = V ( I ) + 1 : Q ( I ) = 0 : F ( I ) = 0 
480 PRINT B (I), INT (F (I) * 1000) I 1000 , Q (I) 
490 NEXT I 
500 FOR I = 1 TO D 
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510 C (I) = (F (I) I L) * 100 
520 NEXT I 
530 Pl = 50 GOSUB 600 GOSUB 960 
540 Pl = 75 GOSUB 600 GOSUB 980 
550 Pl = 90 GOSUB 600 GOSUB 1000 
560 PRINT 
570 PRINT 11 TYPE 1 FOR MORE SAMPLES OR 0 TO END 1 
580 INPUT G 
590 IF G = 1 THEN R = 1 GOSUB 1140 GOSUB 1020 GOSUB 1210 
600 FOR I = 1 TO D 
610 A9 = Pl - C (I) 
620 IF A9 . = 0 THEN GOSUB 650 
630 NEXT I 
640 RETURN 
650 Y2 = C (I) : Yl = C (I - 1) : X2 = B (I) : Xl = B (I - 1) 
660 X3 = Xl + (Pl - Yl) * (X2 - Xl) I (Y2 - Yl) : I = D 
670 PRINT 
680 PRINT II LINEAR INTEWRPOLATION II 
690 D$ = STR$ (Pl) : E$ = "T" : G$ = 11 = 11 
700 F$ = E$ + D$ + G$ 
710 PRINT F$ , X3 
720 RETURN 
730 INPUT "ENTER # OF CALIBRATION POINTS 11 ;N 
740 PRINT 
750 PRINT "INVERSE ENTER 11 ; D$;"INVERSE COMMA AND ABSORB. FOR THAT 
CONC. 11 
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760 REM ******** LEAST SQUARES CALCULATION ************ 
770 FOR I = 1 TO N 
780 INPUT X, Y 
790 Sl = Sl + X 
800 S2 = S2 + Y 
810 S3 = S3 + X "' 2 
820 S4 = S4 + Y ~ 2 
830 S5 = S5 + X * Y 
840 NEXT I 
850 Bl = (N * S5 - S2 * Sl) I (N * S3 - Sl ~ 2) 
860 B2 = (S2 - Bl * Sl} I N 
870 PRINT 
880 PRINT II SLOPE = ";Bl 
890 PRINT " INTERCEPT = ";B2 
900 Sl = Bl * (S5 - Sl * S2 /N) 
910 S4 = S4 - S2 ~ 2 I N 
920 S5 = Sl I S4 
930 S6 = S5 /\. 2 
940 PRINT " CORRELATION DETERMINATION = ";S6 
950 RETURN 
960 X4 = X4 + X3 Y5 = Y5 + X3 * X3 Z7=Z7+1 
970 RETURN 
980 X5 = X5 + X3 Y6 = Y6 + X3 * X3 
990 RETURN 
1000 X6 = X6 + X3 Y7 = Y7 + X3 * X3 
1010 RETURN 
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1020 IF Z7 = 1 THEN 1300 
1030 M4 = X4 I Z7 : M5 = SQR ({Y5 - {X4) A 2 I Z7) I (Z7 - 1)) 
1040 PRINT II MEAN T50 ",M4 
1050 PRINT II STD. DEV. T50 11 , M5 
1060 M6 = X5 I Z7 : M7 = SQR ({Y6 - {X5) I\ 2 I Z7) I (Z7 - 1)) 
1070 PRINT II MEAN T75 11 ,M6 
lOBO PRINT II STD. DEV. T75 ",M7 
1090 MB= X6 I Z7 : M9 = SQR ({Y7 - {X6) A 2 I Z7) I (Z7 - 1)) 
1100 PRINT II MEAN T90 II ,MB 
1110 PRINT II STD. DEV. T90 11 ,M9 
1120 PRINT 11 TOTAL NUMBER OF TABLET RUNS = ",Z7 
1130 RETURN 
1140 FOR I = 1 TO D 
1150 X {I) = B (I) 
1160 S {I) = S (I) + Q (I) * Q (I) 
1170 T (I) = T {I) + Q (I) 
llBO NEXT I 
1200 RETURN 
1210 PRINT II TIME 11 , "MEAN % LABEL", "STD. DEV." 
1220 FOR I = 1 TO D 
1230 Y (I) = T (I) I ( Z7 - V (I)) 
1240 PRINT X {I), (INT (Y (I) * 1000)) / 1000 
1250 PRINT SQR ((S {I) - (T (I) A 2) / (Z7 - V (I))) / ({Z7 - V (I)) -
1)) 
1260 IF {Z7 - V(I)) 4 = 2 THEN PRINT "STD. DEV. SAMPLE 11 ;I; 11 NOT VALID" 
1270 NEXT I 
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1280 PRINT 
1290 PRINT " DO YOU WANT TO RUN ANOTHER SET ? IF YES TYPE RUN" 
1300 END 
226 
( 
( 
( 
APPENDIX II 
A sample program to analyze data from unbalanced factorial design 
General Linear Model - SAS Program 
227 
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( 
10 llLKP101B JOB (LKPlOl), 1 S.R.GHANTA 1 ,MSGCLASS=W,TIME=(0,30) 
20 l*JOBPARM LINES=2 
30 II EXEC SAS 
40 llGO.FTllFOOl DD SYSOUT=A,HOLD=YES 
50 llGO.FT12F001 DD SYSOUT=A,HOLD=YES 
60 llGO.SYSIN DD* 
70 TITLE EFFECT OF BINDER BINDER-CONCENTRATION AND GRANULATING FLUID; 
80 DATA BINDERS; 
90 INPUT ID BINDER B_C GF FLOW REP; 
100 CARDS; 
DATA SET 
800 PROC PRINT; 
810 TITLE2 LISTING OF THE DATA; 
820 PROC GLM; 
830 CLASSES BINDER B_C GF REP; 
840 MODEL FLOW=BINDER B_C GF BINDER*B_C BINDER*GF B_C*GF BINDER*B_C*GF; 
850 I* 
860 II 
A sample output can be found in SAS manual (96). 
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APPENDIX III 
Beer - Lambert's law plots of theophylline, phenylpropanolamine, 
hydrochlorothiazide, phenytoin, and acetaminophen. 
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PHENYLPROPANOLAMINE HYDROCHLORIDE BEER'S PLOT 
.70 
,60 
.so 
LU 
u 
z 
( < CQ 0::: 
0 
Cl) 
CQ 
< 
.30 
.20 
.10 
4 8 12 16 20 24 
CONCENTRATION ( MG/ML X io 3 ) 
230 
( 
FIGURE 82 
THEOPHYLLINE BEER'S PLOT 
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HYDROCHLOROTHIAZIDE BEER'S PLOT 
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PHENYTOIN BEER'S PLOT 
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ACETAMINOPHEN BEER'S PLOT . 
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